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ABSTRACT 
 
Fumonisins are carcinogenic mycotoxins that occur world wide in maize and maize-
based products intended for human consumption. Consumption of fumonisin- 
contaminated maize as a staple diet has been associated with oesophageal and liver 
cancer in South Africa and China. Fumonisin B1 (FB1) inhibits sphingolipid 
biosynthesis and has been implicated in cancer promoting activity in animals and 
humans. FB1 disrupts DNA methylation and induces chromatin modifications in 
human hepatoma (HepG2) cells. In this study FB1 (IC50=200µM) altered liver enzyme 
expression of DNA methyltransferases and demethylases.  DNA methyltransferase 
activities of DNMT1, 3a and 3b were significantly decreased, whilst both DNA 
methylase (MBD2) activity and expression was significantly up-regulated resulting in 
global DNA hypomethylation.  In addition the histone demethylases, KDM5B and 
KDM5C, expression was increased. FACS data confirmed FB1 significantly increased 
global DNA hypomethylation – a process that causes chromatin instability. Next the 
effect of FB1 on miRNA expression was evaluated; FB1 significantly down-regulated 
(11 fold) expression of miR-27b.  MiR-27b modulates expression of human 
cytochrome P450 (CYP1B1) that catalyzes the metabolic activation of many 
procarcinogens. In order to directly assess the effect of miR-27b on CYP1B1 mRNA 
levels, liver cells were transfected with the mimic to miR-27b. CYP1B1 mRNA and 
protein expression was significantly up-regulated by 1.8- fold and 2.6- fold 
respectively.  CYP1B1 is post-transcriptionally regulated by miR-27b suggesting that 
FB1- induced modulation of miR-27b in hepatic cells may be an additional mode of 
hepatic neoplastic transformation.  Finally, the effect of FB1 on the apoptotic pathway 
in HepG2 cells was investigated using an mRNA expression array panel of pro- and 
anti- apoptotic molecules. FB1 significantly increased an AIP family member - BIRC-
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8/ILP-2 (8-fold) in an apoptosis array. In addition, ILP2 protein expression was 
increased (2.3-fold) with a corresponding decrease in Smac/DIABLO protein levels 
(1.7-fold). Further analysis showed an FB1 (0µM, 50µM, 100µM, 200µM) dose-
dependent increase in BIRC-8/ILP-2 mRNA and protein expression in HepG2 cells. 
This data suggests that FB1 modulates apoptosis in a complex dose-dependent 
regulation of pro- and anti-apoptotic molecules – and it is not a matter of simply 
switching on or off.  
In conclusion, the data shows that FB1 possess epigenetic properties by inducing 
global DNA hypomethylation, modulating miRNA expression, and increasing 
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CHAPTER 1 
INTRODUCTION 
Fusarium verticillioides is a ubiquitous soil fungus that infects agricultural crops 
worldwide especially maize.  Fumonisins (series A, B and C) are the major class of 
mycotoxins produced by this fungus, and they all resemble sphingolipids (Merrill et 
al., 1993).  Fumonisin B1 (FB1) inhibits sphingosine N-acetyltransferase and blocks 
sphingolipid biosynthesis.  FB1 has toxicological significance as it is present in high 
concentrations in contaminated crops such as healthy maize plants (Gelderblom et al., 
2001). 
Human populations ingesting maize that is contaminated by F. verticillioides display 
a higher incidence of primary liver cancer (Ueno et al., 1997) and in South Africa and 
China such populations also display a higher incidence of oesophageal cancer 
(Marasas, 1996).  In laboratory experiments, rats developed primary hepatocellular 
carcinoma after being fed a diet containing 50 ppm FB1 (Gelderblom et al., 1992, 
Gelderblom et al., 1994).  Further, FB1 was found to be a potent tumour promoter in 
rat liver after initiation with diethylnitrosamine (Gelderblom et al., 1988).  FB1 cancer 
promoting activity occurred at levels that did not induce liver or kidney toxicity and 
did not initiate cancer.  In summary, these results demonstrate that FB1 possesses 
carcinogenic properties; a US Food and Drug Adminstration (USFDA) study showed 
that FB1 was a kidney carcinogen in rats and a liver carcinogen in mice, respectively 
(Howard et al., 2001).  
Several in vivo studies demonstrated that FB1 induced apoptosis in rat kidney and 
liver (Tolleson et al., 1996, Sharma et al., 1997).  In addition, FB1 induced apoptosis 
in several mammalian cell lines (Tolleson et al., 1996; Wang et al., 1996; Schmelz et 
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al., 1998, Ciacci-Zanella and Jones, 1999).  However, neoplastic African green 
monkey kidney cells (COS-7) were resistant to apoptosis by FB1 as compared to 
normal African green monkey kidney cells (CV-1) (Wang et al., 1996; Ciacci-Zanella 
et al., 1998).  FB1 failed to induce apoptosis in a transformed human leukaemia cell 
line (Ciacci-Zanella et al., 1998) suggesting that transformed cells may be resistant to 
its apoptotic effects.  The ability of cells to escape apoptosis is important in the 
development of cancer, whilst the ability of FB1 to induce apoptosis may select for 
cells resistant to apoptosis. 
In a study on FB1-induced apoptosis in CV-1 and normal MEF mice derived cells, 
cyclin-dependent kinase (cdk) activity increased (not significantly) after three hours, 
but then declined (Ciacci-Zanella et al., 1998). During the early stages of apoptosis a 
transient increase in cdk activity occurs and this was demonstrated in vitro after FB1 
treatment (Zhou et al., 1998).  
Several pathways resulting in apoptosis have been identified (White, 1996).  A study 
on FB1 induced apoptosis in CV-1 cells demonstrated that a baculovirus gene 
(CpIAP) inhibited apoptosis (Jones et al., 2001).  CpIAP blocks apoptosis induced by 
the tumour necrosis (TNF) pathway.  Further support for the TNF signal transduction 
pathway in FB1 -induced apoptosis was the cleavage of caspase-8. CpIAP inhibits 
caspase-8 cleavage and thus prevents FB1 -induced apoptosis (Jones et al., 2001). 
Fumonisin B1 exerts its toxic effects by disruption of sphingolipid biosynthesis and 
accumulation of sphinganine which plays a major role in the modulation of apoptosis 
and cell proliferative pathways related to cancer development (Riley et al., 2001; 
Gelderblom and Marasas 2012; Muller et al., 2012).   FB1 also disrupts the oxidative 
status of liver cells that result in lipid peroxidation (Abel and Gelderblom, 1998). 
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Fumonisin B1 is considered to be a non-genotoxic (epigenetic) carcinogen in risk 
assessment studies (Gelderblom et al., 2008; Muller et al., 2012).  FB1 lacked DNA 
interactive reactivity in different short-term genotoxicity assays using bacteria 
(Gelderblom and Snyman 1991; Knasmuller et al., 1997; Aranda et al., 2000) and in 
vivo and in vitro DNA repair assays in rat liver and primary hepatocytes (Gelderblom 
et al., 1992; Norred et al., 1992; Domijan et al., 2006; Domijan et al., 2007; Domijan 
et al., 2008). 
Epigenetic mechanisms include promoter DNA methylation, histone modifications 
and microRNAs play an important role in the modulation of functional pathways that 
are key to neoplastic development.  In general, epigenetic events occur early in 
neoplasia and many tumour suppressor genes in tumour cells are inactivated by 
epigenetic mechanisms. DNA methylation, a well-known primary epigenetic regulator 
of gene expression, is an important event involved in chemical carcinogenesis (Moggs 
et al., 2004; LeBaron et al., 2010).  Several studies showed that folate deficiency by 
FB1 can cause disruption of DNA methylation and FB1-induced carcinogenesis 
(Stevens and Tang 1997; Abdel Nour et al., 2007). 
A study on rat C6 Glioma cells  showed that FB1 (at concentrations of 9 – 18µM) 
displayed epigenetic properties by inducing hypermethylation of DNA, whilst FB1 
concentrations of 27 and 54µM FB1 decreased methylation (Mobio et al., 2000).  
Another study on a human colon cancer cell line (Caco-2) showed that FB1 (10, 20 
and 40µM) induced hypermethylation, with the 10 and 20µM FB1 concentrations, 
however,at 5µM FB1 concentration– a slight hypomethylation effect was observed 
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(Kouadio et al., 2007).  In these studies the observation of hypermethylation was 
reported and no mechanism was provided.  
Hepatocellular carcinoma (HCC) is the 6th most common cancer in the world (Ferlay 
et al., 2010).  In high risk HCC areas, such as sub-Saharan Africa and eastern Asia, 
major risk factors include chronic hepatitis B virus infection and consumption of 
foods contaminated with mycotoxins.  The carcinogenic potential on FB1 in humans is 
a topic of continuing research.  The USFDA published guidelines recommending that 
total fumonisins in human food be limited to 2ppm (Administration, 2001).  
It was hypothesised that FB1 possesses epigenetic properties that disrupts DNA 
meyhylation; suppresses microRNA expression involved in neoplastic transformation; 
and inhibits apoptosis in human hepatoma cells. 
To test this hypothesis, the study aimed to determine the epigenetic and apoptotic 
effects of FB1 on human liver (HepG2) cells.  The epigenetic effects of FB1 in 
hepatocytes were determined by measuring the global DNA methylation status and 
microRNA profile changes and the biological effects related to cell death.  The 
specific objectives of the study were to investigate the effects of FB1 on: 
• Methylation, especially DNA methyltransferase and demethylase enzymes 
involved in chromatin maintenance and gross changes in structural integrity of 
DNA  
• MicroRNA profile(s) induced and their significance to liver cells, especially 
neoplasia 
• The apoptotic pathway and the mechanism of induction/inhibition 
 
 





Mycotoxins are secondary metabolites produced by fungi and are capable of causing 
disease or death in humans and various animal species. Fungi are usually plant and 
insect pathogens and a small number are classified as disease causing agents in 
vertebrates. Fungi exert detrimental effects either via mycoses or mycotoxicosis 
(Bennett and Klich, 2003). Mycosis is regarded as ‘superficial’ as this is simply the 
growth of the fungus on a host, e.g., athletes foot. Mycotoxicosis caused by secondary 
fungal metabolites, however, is more severe and is often regarded as ‘poisoning by 
natural means’. Mycotoxicosis is common in underdeveloped nations as it arises from 
the exposure and consumption of fungal contaminated food. Although the number of 
people affected by mycosis and mycotoxicosis is not as overwhelming as compared to 
viral, protozoan and bacterial infections, it is still regarded as a serious international 
health problem (Bennett and Klich, 2003). 
There are approximately four hundred compounds that have been classified as 
mycotoxins since 1960 following the outbreak of ‘turkey X’ syndrome caused by 
aflatoxin B1, a secondary metabolite produced by Aspergillus flavus. The fumonisins 
were described and characterised in 1988 and has created controversy about the 
occurrence and effects of these mycotoxins due to their hydrophilic nature (Bennett 
and Klich, 2003).  
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2.1.2. Fumonisin 
Fumonisins are naturally occurring secondary metabolites produced predominantly by 
Fusarium verticillioides (Sacc.) Nirenberg (formerly known as F. moniliforme 
Sheldon) and F. proliferatum (Matsushima) Nirenberg (Marasas, 2001). These 
mycotoxins occur world wide in many agricultural grains, especially in maize (Zea 
mays L.) and maize-based products intended for human and animal consumption 
(Shephard et al., 1996). Poor storage conditions is the leading cause of contamination, 
where fungi favour moist, humid and dark conditions to grow (Heidtmann-
Bemvenuti, 2011). To date, 28 fumonisin analogues have been identified and 
categorised into A, B, C and P series (Rheeder et al., 2002).  Fumonisin B1, B2, and 
B3 (FB1, FB2 and FB3) are the most abundant naturally occurring fumonisins (Figure 
2.1) of which FB1 is the most significant analogue. FB1 is also the major contaminant 
mycotoxin in cereal grains such as maize (Shephard et al., 1992; Rheeder et al., 
2002).  The FB series have a free amine group at the C-2 position  in contrast to the 
FA series that are acetylated on the amino group at the same position; the FC series 
have no methyl group at the C-1 position and the FP series have a 3-
hydroxypyridinium group at the C-2 position (Bezuidenhout et al., 1988; Musser et 
al., 1996). 
2.1.21.  Fumonisin B1 
Fumonisin B1, the most toxic of the fumonisins, has a wide range of toxic effects in 
both humans and animals. It has also been classified as a possible class 2B carcinogen 
by the International Agency for Research on Cancer (IARC).  South Africans are 
continuously exposed to doses of FB1 with an estimated daily dietary intake of 
200µg/kg body weight (Domijan and Abramov; 2011). 
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2.1.2.2. Chemical structure 
The chemical structure of FB1 is based on a hydroxylated hydrocarbon chain rather 
than a cyclic structure most commonly associated with mycotoxins (Shephard et al., 
1996). FB1 is a diester of propane-1,2,3-tricarboxylic acid (TCA) and 2-amino-12,16-
dimethyl-3,5,10,14,15-pentahydroxyeicosane, in which the C14 and C15 hydroxyl 
groups are esterfied with a terminal carboxyl group of TCA (Figure 2.1A) (Soriano et 
al., 2005; Heidtmann-Bemvenuti, 2011). The chemical structure of FB1 resembles the 
sphingoid bases: sphinganine (Sa) and sphingosine (So) (Figure 2.1 B and C) - 
important precursors in sphingolipid biosynthesis. The sphingoid bases consist of an 
amine and two alcohol groups attached to a 3C chain that is attached to a long 
hydrocarbon chain (Figure 2.1B and C). This structural similarity is critical for FB1 
toxicity because it disrupts sphingolipid metabolism. The free amino group in FB1 
(Figure 2.1A) creates an amino pentol backbone that is important in FB1 toxic activity 
where it competes with the sphingoid bases in the biosynthesis of sphingolipids 

















Figure 2.1: Chemical structure of (A) Fumonisin B1 and its similarities to sphingoid 
bases (B) Sphinganine ad (C) Sphingosine (Griessler 2008). 
2.1.3. Absorption, Metabolism and Distribution of Fumonisin B1  
Fumonisin B1 is a polar mycotoxin and is a 1, 2, 3-Propanetricarboxylic acid, 1, 1’-[1-
(12-amino-4, 9, 11-trihydroxy-2-methyl-tridecyl)-2-(1-methylpentyl)-1, 2-ethane-
diyl] ester. The structure of FB1 was elucidated by Bezuidenhout et al. (1988) 
(Bezuidenhout et al., 1988). The polarity of the molecule is due to the presence of 
hydroxyl groups and tricarballylic acid side chains (Figure 2.1) (Carratu et al., 2003). 
Fumonisin B1 has not been found to be absorbed via the pulmonary system although 
the potential exists due to the presence of the toxin in mycelia, spores and 
conidiophores (Tejada-Simon, 1995). The absorption of FB1 through skin is 
negligible because FB1 is a polar molecule and thus very water soluble, and therefore 
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site of absorption, however, is in the small intestine following consumption of 
contaminated maize and maize based products (Shephard et al., 1996).  
There is little evidence of FB1 metabolism, but the minor metabolism of FB1 involves 
the partial and complete hydrolysis of the toxin which is thought to occur in the 
intestine, by intestinal microflora. The hydrolysis of FB1 results in the removal of 
either one or two propane tricarboxylic acid residues (Shephard et al., 1994). The 
hydrolysis metabolites are easily absorbed in the intestine but a major portion of the 
toxin remains unmetabolised in the feaces and excretory products. Although the 
presence of FB1 in the organism results in increased induction of Cytochrome (Cyt) 
P450-1A1 and Cyt P450-4A1 activities, there is no evidence that the enzyme system is 
responsible for biotransformation of the toxin (Martinez-Larranaga et al., 1996). 
The poor absorption of FB1, rapid distribution to tissues and elimination is common to 
several species of animals including rodents, pigs, vervet monkeys, cows, rats and 
hens.  
In rodents, absorption of FB1 treated with an oral dosage of 10mg/kg body weight was 
shown to be approximately 3.5% of the dose reaching a maximum plasma 
concentration of 0.18µg/ml. The distribution of the absorbed dose was matched to a 
two compartment open model which displayed elimination half-lives of 3.15hrs for 
plasma, 4.07hrs for the liver and 7.07hrs for kidney (Martinez-Larranaga et al., 1999). 
This study concluded that FB1 accumulated in the liver and kidney with ratios of 2.03 
and 29.9 compared to plasma concentration. In 2006 Riley and Voss confirmed these 
findings in an experiment where rodents were fed a fumonisin-spiked diet over three 
weeks. Using HPLC it was determined that the concentration of the toxin in the 
kidney was ten-fold greater than that of the liver (Riley and Voss, 2006). 
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Prelusky et al. (1994, 1996) analysed the bio-distribution of FB1 in pigs and showed a 
similar pattern to that determined in the rodent model (Prelusky et al., 1994; Prelusky 
et al., 1996). The absorption and elimination was rapid and low tissue residues were 
detected. The pigs in this study were dosed intravenously with 0.4mg/kg body weight 
of radiolabelled FB1. Recovery of the toxin from urine was determined to be 0.76 to 
0.83 of the dose after 72hrs. Tissue recovery was approximately 0.12 of the dose with 
highest activities in the liver and kidney. Results from intragastric dosing of 0.5mg 
radiolabelled FB1/kg body weight however, demonstrated that the bioavailability was 
approximately 0.041 of the dose (Prelusky et al., 1996) and 0.005 of the dose was 
excreted in the urine. The studies by Prelusky concluded that absorption of FB1 from 
feed is low, but is retained in tissue over a prolonged period of time, and accumulates 
in the kidney and the liver preferentially (Prelusky et al., 1996).  To date, no such data 
on human is available. 
Studies conducted in ruminants suggest that FB1 is taken up poorly, with 0.80 of the 
total dosage recovered unmetabolised in feaces, poorly taken up by tissues and 
diminutive amounts found in urine (Prelusky et al., 1995; Smith and Thakur, 1996). 
Similarly, intravenous administration of radiolabelled FB1 (2mg/kg body weight) to 
laying hens was rapidly eliminated with very low distribution to tissues, particularly 
the liver and kidneys.  
The small amount of FB1 which is absorbed in animal systems accumulates in the 
kidney and liver tissue (Norred et al., 1992; Shephard et al., 1992; Prelusky et al., 
1994; Prelusky et al., 1996; Smith et al., 1996) resulting in hepatotoxicity and 
nephrotoxicity.  
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2.1.4. Mechanism of Action of Fumonisin B1 
Fumonisin B1 is a structural analogue of sphinganine and sphingosine, important 
substrates in sphingolipid metabolism. The biochemical mode of action of FB1 
includes the disruption of sphingolipid metabolism (Wang et al., 1991). In order to 
understand the mechanism of toxicity of FB1 it is important to understand the 
biosynthesis and biological function of sphingolipids.   
Sphingolipid biosynthesis occurs de novo through a series of reactions (Merrill and 
Jones, 1990). The condensation of serine with palmitoyl-CoA catalysed by serine 
palmitoyltransferase results in the formation of 3-ketosphinganine which is reduced to 
sphinganine (Sa) using NADPH. Sphinganine is then acylated to dihydroceramides by 
ceramide (CER) synthase by the utilisation of fatty acyl-CoA’s, or phosphorylated to 
form sphinganine-1-phosphate. The desaturation of dihydroceramide results in the 
production of CER. Further conjugation of phosphocholine or oligosaccharides to 
ceramide produces complex sphingolipids (CSL). Catalytic reactions of complex 
sphingolipids during turnover involve the hydrolysis of sphingolipids producing CER, 
followed by the hydrolysis of CER to produce sphingosine (So) (Figure 2.2).  
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Figure 2.2: The de novo synthesis of sphingolipids in animal cells; the points at which 
Fumonisin B1 disrupts this process indicated by X (Voss et al., 2006). 
Fumonisin B1 disrupts the metabolism of sphingolipids by competitive inhibition of 
CER synthase (Figure 2.2). The aminopentol (AP1) backbone of FB1 competes for the 
sphingoid base substrate and the anionic tricarballylic acids interfere with fatty acyl-
CoA binding. Microflora in primate intestines have the ability to hydrolyse FB1 to 
AP1 (Merrill et al., 2001). Ceramide synthase inhibition causes an accumulation of Sa 
and So, a decrease in CER and concentration-dependant depletion of CSL. Sphingoid 
bases, CER and sphingolipids are important structural molecules of cell membranes 
and are regulators of cellular functions.  
The consequences of the inhibition of ceramide biosynthesis for cells are: 
• Cell death normally induced by CER 
• Ceramide mediated apoptosis of oxidant damaged cells to avert 
accumulation of damaged DNA in cells 
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• Activation of mitogen activated protein kinases in Swiss 3T3 cells 
• Promotion of free sphingoid base accumulation  
• Dephosphorylation of retinoblastoma protein, repression of cyclin 
dependent kinase (CDK) 2 and induction of CDK inhibitors in CV-1 cells  
• Apoptosis inhibitor and protease inhibitor protection of CV-1 cells and 
primary human cells from FB1 induced apoptosis (Riley et al., 2001). 
2.1.5. Elimination of Fumonisin B1 
Excretion of FB1 after intra peritoneal dosage appeared to be different in rats and pigs. 
In rats, the initial elimination is rapid with a half-life of 10-20mins (Norred et al., 
1993; Shephard et al., 1994). In the pig, the half-life is described to be a three 
compartment model, with values of 2.5, 10.5 and 183mins. The enterohepatic 
circulation is important for the removal of FB1 using bile, as studies show that the 
absence of this path of elimination increases the half-life of the toxin to 96mins 
(Marasas et al., 2004).   
2.1.6. Toxic effects of Fumonisin B1 in vivo and in vitro 
Reported animal diseases due to FB1 exposure include the fatal neurotoxic syndrome, 
equine leukoencephalomalacia (ELEM) (Marasas et al., 1988), porcine pulmonary 
oedema (PPO) syndrome (Kriek et al., 1981), hepatotoxicity in non-human primates 
(Kriek et al., 1981), and hepatotoxicity in mice and nephrotoxicity and hepatoxicity in 
rats (Tolleson et al., 1996).  
The ELEM syndrome has been shown to be specific to equids but there are studies 
that have been conducted on rabbits which showed brain lesions and haemorrhaging. 
The characteristic feature of ELEM is the presence of liquefactive necrotic lesions in 
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the white matter of the cerebrum. Marasas et al. (1988) showed that grey matter may 
also be affected (Marasas et al., 1988). 
Kriek et al. (1981) were the first to report PPO following an experimental trial in 
which horses, sheep, rats, baboons and pigs were exposed to culture material of F. 
verticilloides (Kriek et al., 1981).  The hypothesised mechanism of PPO is by the 
dysfunction of pulmonary interstitial macrophages resulting in the release of 
vasoactive mediators (Haschek et al., 1992). Studies conducted to screen maize on 
different farms on which PPO outbreaks occurred, showed a strong correlation 
between maize fungal contamination and PPO prevalence (Osweiler et al., 1992). In 
pigs, the kidney was also a target of fumonisin toxicity (Colvin et al., 1993; Harvey et 
al., 1995).   
During a non-human primate study, three baboons were fed F. verticilloides culture 
material. Two of the baboons died of acute congestive heart failure, while the third 
survived up to 720 days at which point it was sacrificed. An autopsy of the third 
baboon revealed liver cirrhosis (Kriek et al., 1981). Vervet Monkeys fed F. 
verticilloides culture material over 180 days showed chronic hepatotoxicity which 
resulted in an increase in serum cholesterol, plasma fibrinogen and factor VII 
(Fincham et al., 1992).  
Numerous acute and chronic studies on rats and mice demonstrated FB1 induced  
hepatoxicity, nephrotoxicity, immunotoxicity, reproductive toxicity, embryotoxicity, 
teratogenicity, mutagenicity and carcinogenicity.  
Voss et al. (1995) showed that FB1 produced kidney lesions in rats and mice. The 
proximal tubule located in the outer medulla was found to have lesions in both male 
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and female rats; however the concentration of FB1 that resulted in these lesions was 
different between males and females (Voss et al., 1995).  
Balb/C mice exposed to a range of FB1 concentrations (0.25 – 6.25mg/kg body weight 
per day) by subcutaneous administration showed a dose-dependent increase in 
apoptosis in the liver and the kidney (Sharma et al., 1997).  
Apoptotic renal tubule epithelial cells in Fischer-344 rats were observed by Tolleson 
et al. (1996) following exposure to 0, 99, 163, 234 and 484mg FB1/kg in the diet 
(Tolleson et al., 1996).  
Fumonisin B1 has also been shown to display genotoxic properties using human 
derived hepatoma cells, human fibroblasts, rabbit kidney cells (Galvano et al., 2002), 
rat C6 glioma cell (Rumora et al., 2007) rat astrocytes and p53 null mouse embryo 
fibroblasts (Mobio et al., 2000).  
2.1.7. Carcinogenic potential of Fumonisin B1  
Treatment of rats with FB1 caused acute and chronic liver toxicity, bile duct 
proliferation, fibrosis further developing into cirrhosis, cholangiogenesis and 
hepatocellular carcinoma and/or cholangiocarcinoma (Gelderblom et al., 1988; Voss 
et al., 1993). Although the findings regarding the FB1-related tumour genesis in 
humans are speculative, FB1 has been associated with the high incidences of 
oesophageal cancer endemic in Transkei, South Africa (Dutton, 1996) and in China 
(Li et al., 1980). A different form of tumour, primary liver cancer, was also linked to 
FB1 consumption in Haimen province, China (Li et al., 1980). The carcinogenic 
properties of FB1 observed in rodents are not associated with its direct genotoxicity. 
As a potent promoter of apoptosis, FB1 causes further regeneration that is 
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characterized by increased cell proliferation in affected tissues. Consequently, the 
constant increase of DNA replication in exposed tissues may increase the likelihood 
of cancer induction (Riley et al., 2001). The International Agency for Research on 
Cancer (IARC) has declared toxins of F. verticillioides (including FB1) as potential 
human carcinogens graded as class 2B (Vainio et al., 1993).  
Studies from South Africa, Iran and China indicate a correlation between the 
prevalence of oesophageal cancer in humans (Figure 2.3) and the consumption of 
maize containing high levels of FB1 (Wilson et al., 1990; Chu and Li 1994; 
Yoshizawa et al., 1994; Mosavi-Jarrahi and Mohagheghi, 2006; Eslick 2009). South 
Africans are continuously exposed to low doses of FB1 with a daily dietary intake of 
200µg/kg body weight (Domijan and Abramov, 2011).  
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Figure 2.3 The geographical representation of oesophageal cancer incidence between 
males and females in 2009; A: incidence of oesophageal cancer in males, B: incidence 
of oesophageal cancer in females  (Eslick, 2009). 
The challenge in toxicology research is integration of knowledge from diverse fields 
novel technological developments in the biological and medical sciences.    
2.2. Toxicology and Cancer  
2.2.1. Epigenetics and Cancer 
According to the World Health Organisation (WHO), cancer is the leading cause of 
death, accounting for approximately 14.1 million newly diagnosed cases and 8.2 
million deaths in 2012 (Ferlay et al., 2013). Genetic and epigenetic modifications 
have been considered as two distinct mechanisms associated with the initiation and 
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progression of cancer. Cancer has traditionally been seen as a set of diseases that 
occur due to the accumulation of genetic changes (Hanahan and Weinberg, 2011). 
Genetic changes include those that alter nucleotide sequences of the genome leading 
to chromosomal loss or gain, loss of heterozygosity and amplification or mutations of 
genes. More recently, however, it is recognised that cancer is also a result of abnormal 
epigenetic events (Sawan et al., 2008; You and Jones 2012). Alterations in the 
regulation of gene expression that do not involve a change in the DNA sequence is an 
important key event of carcinogenesis, referred to as “epigenetic’’ changes. 
Epigenetic mechanisms include the methylation of cytosines in DNA, changes of 
histone and chromatin and variations in the expression of microRNAs (miRNAs) 
(Kelly et al., 2010; You and Jones 2012; Akhavan-Niaki and Samadani, 2013). 
2.2.1.1.  DNA Methylation and Cancer 
DNA methylation is an important biochemical process involved in normal 
development of higher organisms.  One of the hallmarks of cancer is aberrant DNA 
methylation.  The process involves the addition of a methyl group to the 5’ position of 
the cytosine ring or the nitrogen 6 of the purine ring of adenine.  This modification 
can be inherited through cell division.   
In normal organism development and cellular differentiation, DNA metylation 
constantly changes gene expression patterns in cells.  DNA methylation forms the 
basis of chromatin structure.  It also plays a crucial role in the development of many 
types of cancers (Singal and Ginder, 1999; Docherty et al., 2010).  Changes in DNA 
methylation patterns or in DNA methyltransferase expression may play a role in the 
onset or course of cancer (Baylin and Bestor, 2002). Methylation is mainly restricted 
to the palindromic CpG sequence.  The methyl-CpG-dinucleotide represents a 
	   19	  
mutational hotspot as it can undergo spontaneous deamination to produce thymine 
(Bird, 2002).  DNA methylation is carried out by DNA methyltransferase (DNMT) 
enzymes (Figure 2.4) (Frémont et al., 1997).  The most common DNMTs are 
DNMT1, DNMT3a and DNMT3b.  Methylation can be de novo (CpG dinucleotides 
on both DNA strands are unmethylated) or maintenance (CpG dinucleotides on one 
DNA strand are methylated).  DNMT1 has de novo as well as maintenance 
methyltransferase activity, while DNMT3a and DNMT3b are powerful de novo 
methyltransferases (Monk et al., 1991).   
In addition to the DNMTs, other members of the methylation function include 
demethylases, methylation centres that trigger DNA methylation or methylation 
protection centres (Cooper and Krawczak, 1990).   The enzymes that demthylate 
DNA include 5-methylcytosine glycosylase, which removes the methylated cytosine 
from DNA, leaving the deoxyribose intact, and MBD2b, an isoform from the 
initiation of translation at the second methionine codon of the gene encoding methyl-
CpG binding domain 2 (MBD2) protein (Dar et al., 2013).  MBD2 lacks glycosylase 
or nuclease activity and is thought to cause demethylation by hydrolysing 5-
methylcytosine to cytosine and methanol (Figure 2.4) (Yen et al., 1992; Vairapandi 
and Duker 1993; Ehrlich, 2002).  
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Figure 2.4: The process of methylation and demethylation of cytosine by DNA methyl 
transferases (DNMT) and methyl domain binding protein (MDB2) (Korzus, 2010). 
Hypomethylation, follows hypermethylation in the ranks of epigenetic changes 
responsible for a wide variety of malignancies (Kim et al., 1994; Jones and Baylin, 
2007). Hypomethylation is often seen in solid tumours such as metastatic 
hepatocellular cancer (Wilson et al., 2007), in cervical cancer (Kim et al., 1994), as 
well as in B-cell chronic lymphocytic leukaemia (Ehrlich, 2002). The global 
hypomethylation seen in a number of cancers, such as breast, cervical, and brain, 
show a progressive intensification as the grade of malignancy worsens (Ehrlich, 
2002). Hypomethylation has been thought to contribute to oncogenesis by activation 
of oncogenes such as cMYC and H-RAS75 (Singer-Sam and Riggs, 1993, Alves et al., 
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2.2.1.2. MicroRNAs and Cancer 
Cancer is defined as uncontrolled proliferation of functionally compromised/damaged 
cells, which results in tumour formation. Cells have developed several safeguards to 
ensure that cell division, differentiation and death occur in a harmonized manner 
during development and repair of the body. Various regulatory factors switch genes 
on or off thereby controlling cellular proliferation and differentiation. Damage to the 
genes involved in proliferation and differentiation are referred to as tumour-
suppressor genes and oncogenes when they are affected and results in cancer. Most 
tumour suppressor genes and oncogenes are first transcribed from DNA into RNA, 
and are then translated into protein to exert their effects. Recent evidence indicates 
that small non-protein-coding RNA molecules, called microRNA (miRNA), also 
function as tumour suppressors and oncogenes and are referred to as ‘oncomirs’ 
(Shenouda and Alahari, 2009). Approximately half of the annotated human miRNAs 
fall within regions of chromosomes, which are areas of the genome that are associated 
with various human cancers (Esquela-Kerscher and Slack, 2006; Baylin and Jones 
2011). 
MicroRNAs are important regulators of of gene expression.  Alteration of miRNA 
expression casued by exposure to FB1 (not well documented) may lead to chemical 
carcinogenesis.  Many miRNAs deregulated by carcinogens are involved in regulation 
of genes important in chemical carcinogenesis, including xenobiotic metabolism, 
carcinogen-induced hypomethylation, apoptosis, cell transformation, oncogenesis, etc.  
The carcinogenic functions of carcinogens may be dependent on the balance between 
tumour suppressor miRNAs and oncogenic miRNAs. 
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2.2.1.3. MicroRNAs  
MicroRNAs are single-stranded non-coding RNA strands of 19-25 nucleotides in 
length that are thought to regulate the expression of as many as one-third of all human 
mRNAs (Marquez and McCaffrey, 2008). The first miRNAs was identified in C. 
elegans in 1993 (Lee et al., 2003). Currently there are 1881 homosapien sequences 
registered in the miRBase database.  Each miRNA can regulate many target genes and 
several miRNAs may affect a single gene (Di Leva et al., 2014).  Recent evidence 
shows that miRNAs are found to be involved in many regulatory processes such as 
cellular proliferation, differentiation, cell cycle regulation, angiogenesis metabolism, 
regulation of the immune response and apoptosis (Kato and Slack 2008; O'Connell et 
al., 2010). 
2.2.1.4. MicroRNA biogenesis 
There are two main miRNA biogenesis pathways – a canonical and an alternate 
pathway.  The canonical pathway driven by RNase III enzymes generate the majority 
of animal miRNAs (Ghildiyal and Zamore, 2009).  The biogenesis starts with RNA 
polymerase II-dependent transcription of a miRNA gene locus, generating a long 
primary transcript known as pri-miRNA that can fold into a hairpin structure (van 
Kouwenhove et al., 2011).  Pri-miRNAs are cleaved into approximately 70-nucleotide 
precursor-miRNAs (pre-miRNAs) by the microprocessor complex that contains a 
RNase III enyme called Drosha and its cofactor DGCR8 (DiGeorge syndrome critical 
gene 8) (Han et al., 2006).  DGCR8 is dsRNA binding protein that recognises the 
proximal ~10bp stem of the pri-miRNA hairpin, positioning the catalytic sites of the 
RNase III enzyme Drosha (Di Leva et al., 2014).   
	   23	  
Mitrons are a subset of miRNAs which utilise the alternative pathway for miRNA 
biogenesis (Ruby et al., 2007).  These miRNAs are located within short introns, and 
once splicing is complete, a debranching enzyme generates the pre-miRNA-like 
hairpin (Figure 2.5) (Baley and Li 2012).  The pre-miRNAs are recognised by a 
complex of exportin-5 (Exp5) and RAN-GTP (van Kouwenhove et al., 2011).  The 
pre-miRNAs are then exported to the cytoplasm by Exp5, where they are cleaved into 
mature 20-25 nucleotide miRNA duplexes by another RNAse III endonuclease, 
DICER, and by its double stranded RNA binding cofactor the RNA-binding protein: 
trans-activation response (TAR) RNA binding protein (TRBP), among other proteins 
(Figure 2.5) (Winter et al., 2009, Bronze-da-Rocha, 2014).  While the passenger 
strand is typically degraded, the guide strand is incorporated into RNA-induced 
silencing complex (RISC) and then mediates mRNA degradation or translational 
inhibition (D'Anzeo et al., 2014) ( Figure 2.5).  
MicroRNAs regulate gene expression by acting as RNA silencers or post-
transcriptional gene regulators (Baylin and Jones, 2011).  
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Figure 2.5 The process of miRNA biogenesis, maturation and regulation (Esquela-
Kerscher and Slack, 2006). 
The potential sites of regulation of gene expression by miRNAs are represented in 
intronic miRNAs encoded within the same protein code transcript that regulates 
similar processes of that protein; a single miRNA targets several mRNA targets 
involved in the same biological process, several miRNAs regulate the same biological 
process by targeting individual components of a pathway and miRNAs target 
molecules that are involved in the regulation of a specific process (Baylin and Jones, 
2011). As with all cellular processes, abnormal regulation of the expression of 
miRNAs has been linked to the onset and progression of numerous malignancies 
(Figure 2.6).  
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Figure 2.6 MicroRNAs function in A: normal tissue, B: as a tumour suppressor and C: 
as an oncogene (Esquela-Kerscher and Slack, 2006). 
  
MicroRNAs can function as tumour suppressors and oncogenes by the reduction or 
complete deletion of a miRNA (that functions as a tumour suppressor) - leading to 
tumour formation (Figure 2.6b).  A reduction in or elimination of mature miRNA 
levels can occur because of defects at any stage of miRNA biogenesis and ultimately 
leads to the inappropriate expression of the miRNA-target oncoprotein. The overall 
outcome might involve increased proliferation, invasiveness or angiogenesis, 
decreased levels of apoptosis, or undifferentiated or de-differentiated tissue, leading to 
tumourigenesis (Esquela-Kerscher and Slack, 2006).  
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The amplification or overexpression of a miRNA that has an oncogenic role would 
also result in tumourigenesis. In this condition, increased expression of a miRNA, 
produced inappropriately, either when not required or in the incorrect tissues, would 
eliminate the expression of a miRNA-target tumour-suppressor gene and lead to 
cancer progression (Figure 2.6c). Increased levels of mature miRNA might occur 
because of amplification of the miRNA gene, a constitutively active promoter, 
increased efficiency in miRNA processing or increased stability of the miRNA 
(Esquela-Kerscher and Slack, 2006). 
 
The role of toxins (environmental pollutants and mycotoxins) on the aberrant 
epigenetic function has yet to be elucidated. The link between degree of exposure and 
epigenetic alterations has not been established and the in vitro model of hepatocellular 
carcinoma provides an ideal platform to interrogate plausible mechanisms of toxicity. 
The first stage of carcinogenesis is initiation (genetic changes of DNA in a cell).  
DNA damage can occur due to interactions between genotoxic agents (FB1) and 
DNA.  If the damaged DNA is not properly repaired, then this damaged DNA could 
be fixed into mutations that can predispose the cell to become cancerous.   
 
2.3. Toxicology and Apoptosis 
2.3.1. Overview 
Programmed cell death, also referred to as apoptosis, is an important physiological 
process regulating homeostasis of cell numbers during development and throughout 
an organisms life, by facilitating the removal of irreparable damaged or undesirable 
cells (Orrenius et al., 2011).  
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During apoptosis, organelle integrity is maintained and minimal leakage of 
intracellular contents occurs, thereby preventing an inflammatory response (Slater et 
al., 1995). This distinguishes the process of apoptosis from necrosis.  
It has been hypothesised that the dysregulation of the apoptotic process tends to play 
an integral role in the pathogenesis of human diseases and pathological conditions 
(Kaufmann and Hengartner, 2001). Cancer for example, is a disease characterised by 
little or no apoptosis due to mutations that reduce the susceptibility of cells to 
apoptosis. Therefore, the understanding of the apoptotic mechanisms and its role in 
cancer development is essential in relation to toxicology, specifically to that of FB1 
which has been shown to possess both pro- and anti-apoptotic activities (Jones et al., 
2001; Zimmermann et al., 2001; Voss and Riley 2013). 
2.3.2. The extrinsic and intrinsic pathways of apoptosis 
During the early stages of apoptosis a family of aspartate-directed cysteine (caspases) 
proteases, induces the cleavage of important cellular substrates required for normal 
function. The caspases selectively mediate the cleavage of downstream substrates for 
the execution of apoptosis (Figure 2.7) (Orrenius et al., 2011). 
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Figure 2.7 The activation of the extrinsic and intrinsic pathways of apoptosis 
(Orrenius et al., 2011). 
The biochemical features of apoptosis include internucleosomal cleavage of DNA 
which leads to an oligonucleosomal ‘‘ladder’’ and phosphatidylserine (PS) 
translocation from the inner to the outer cell membrane. These processes induce 
morphological distinctions that define apoptotic cells such as membrane blebbing, 
condensation of chromatin, nuclear fragmentation, loss of adhesion and cell shrinkage 
(Zimmermann et al., 2001).  
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The extrinsic and intrinsic pathways represent the two major well-studied apoptotic 
processes (Figure 2.7) (Hassan et al., 2014).  Apoptosis may be triggered by various 
stimuli depending on the intracellular functionality or interactions of cell membrane 
associated death receptors (DRs) with specific stimuli. Death receptors are cell 
surface receptors that facilitate the communication of apoptotic signals initiated by 
ligands. Cell surface DRs belong to the TNF receptor (TNFR) superfamily. The best-
characterised family members include Fas (CD95) and TNFR1 (Orrenius et al., 2011). 
Binding of extracellular ligands, such as Fas to its related receptor induces 
trimerisation of the receptor (Song and Steller, 1999). After trimerisation and 
activation of DRs, other proteins are recruited and serve as adaptor molecules in the 
signal transduction cascade.  
During the activation of the extrinsic pathway the adaptor molecule Fas-associated 
death domain (FADD) associates with Fas which mediates its association with death 
effector domain (DED) containing protein: pro-caspase-8.  The complex of Fas, 
FADD and pro-caspase-8, known as the death inducing signalling complex (DISC),  
then releases active caspase-8 into the cytosol (Kaufmann and Hengartner, 2001). 
Once caspase-8 is activated, the execution phase of apoptosis is triggered.  Initiator 
caspase-8 may either directly activate downstream effector caspases -3 and -7 that 
execute apoptosis or cleave the pro-apoptotic protein, BH3-interacting-domain death 
agonist (Bid), to truncated Bid (tBid) resulting in activation of an additional 
mitochondrial loop (Song and Steller 1999; Elmore, 2007). Truncated Bid then causes 
the release of the mitochondrial proapoptotic factors: cytochrome c (cyt-c) , Smac 
(second mitochondrial activator of caspases)/DIABLO, AIF (apoptosis inducing 
factor) and endonuclease G. Thus Bid through its effect on the mitochondrial 
membrane potential interacts with the intrinsic pathway (D’Archivio et al., 2008). 
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The intrinsic signalling pathway (also known as the mitochondrial mediated apoptotic 
pathway)  that initiates apoptosis involves a diverse array of non-receptor-mediated 
stimuli that produce intracellular signals that act directly on targets within the cell and 
are mitochondrial initiated events (Elmore, 2007).  A multitude of diverse stress 
signals, including cytotoxic stress, oxidative stress, heat shock or DNA damage 
initiate the inrinsic pathway of apoptosis. These triggers cause the release of cyt-c 
from the mitochondrial intermembrane space into the cytoplasm. The release of cyt-c 
causes the activation of downstream molecules responsible for the final execution of 
apoptosis (Chowdhury et al., 2009).  
Under normal cellular conditions, cyt-c is found in the inner mitochondrial membrane 
bound to cardiolipin (Prétet 2002). Once released, cyt-c interacts with apoptotic 
protease-activating factor-1 (APAF-1) and pro-caspase-9 forming an apoptosome 
which is also known as the active form of caspase-9.  Caspase-9 can then directly 
activate caspase-3 and -7, resulting in cell death by tightly regulated proteolytic 
processing of downstream targets.  
During the release of cyt-c, the mitochondrial factor, AIF (a flavoprotein) is also 
released from the mitochondrion and translocates to the nucleus. In the nucleus, AIF 
causes DNA fragmentation and chromatin condensation (Kaufmann and Hengartner, 
2001). Mitochondria also release endonuclease G, which is involved in DNA 
degradation associated with apoptosis (Kaufmann and Hengartner, 2001). 
2.3.3. Inhibitors of apoptosis (IAP) 
The apoptotic cascade is regulated by both initiators and inhibitors and can be 
activated by diverse stimuli.  The inhibitor of apoptosis (IAP) family of proteins plays 
a central role in apoptotic and inflammatory processes, conferring protection against 
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cell death.  The IAP family members interfere with the transmission of intracellular 
death signals inhibiting caspase-dependent apoptotic pathways (Figure 2.8).  The IAP 
proteins were initially identified in baculovirus as factors that prevented host cell 
apoptosis, allowing time for the virus to replicate (Crook et al., 1993; Clem and 
Miller, 1994).  To date, eight IAP-family members have been identified in human 
cells: NAIP (BIRC1), c-IAP1 (BIRC2), c-IAP2 (BIRC3), XIAP (BIRC4), Survivin 
(BIRC5), Bruce (BIRC6), Livin (BIRC7) and ILP-2 (BIRC8) (Vucic and Fairbrother, 
2007).   
The IAP proteins exibit a modular structure characterised by the presence of one or 
more baculovirus IAP repeat (BIR) domains.  The BIR domain has a zinc-binding 
fold of ~70 amino acid residues that is essential for the anti-apoptotic properties of 
IAP proteins. The fact that all known IAP members have a BIR domain suggests that 
this domain plays a pivotal role in mediating cellular protection (De Almagro and 
Vucic, 2012).  Some members of this family (XIAP, c-IAP1, c-IAP2 and Livin) also 
have a RING domain that allows these proteins to act as E3 ubiquitin ligases 
(Eckelman et al., 2006).  E3 ubiquitin ligase activity gives IAPs the ability to promote 
the ubiquitination and subsequent proteasomal degradation of caspases, TRAF2, and 
additional partners (Vucic and Fairbrother, 2007). Several studies indicate that IAPs 
may play a role in oncogenesis (Hunter et al., 2007; LaCasse et al., 2008).   
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Figure 2.8 The inhibitors of apoptosis (IAP) protein function as caspase inhibitors 
halting the execution phase of apoptosis (Hunter et al., 2007). 
Caspase inhibition occurs mainly by binding to the unique BIR domains of IAP.  
NAIP, c-IAP1, c-IAP2 and XIAP have three BIR domains, the third BIR domain 
mediates the binding to, and inhibition of caspase-9, an initiator caspase capable of 
processing and thereby activating other caspases (Srinivasula et al., 2001).  Interaction 
of caspase-9 with the third BIR domain of IAPs prevents its homodimerisation, 
inhibiting its activity (Shiozaki et al., 2003).  The second BIR domain mediates the 
interaction of IAPs with caspase-3 and -7, the effector caspases that are activated by 
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initiator caspases (Figure 2.8).  In summary, the binding of IAPs to caspases prevents 
the interaction between caspases and their cellular substrates, thus inhibiting the 
proteolytic degradation of the cell that marks the final execution stage of apoptosis 
(Chai et al., 2001).   
2.3.4. Second-mitochondria-derived activator of caspases (Smac) 
The mitochondrial protein Smac/DIABLO performs a critical function in apoptosis by 
eliminating the inhibitory effect of IAPs on caspases.  Concurrent with cyt-c release, 
Smac is also released from the mitochondria into the cytosol.  Whereas cyt-c induces 
multimerisation of Apaf-1 to activate procaspase-9 and -3, Smac eliminates the 
inhibitory effect of many IAPs (Chai et al., 2001).  Thus Smac interacts with all IAPs 
and appears to be a master regulator of apoptosis in mammals.   
There is limited epigenetic data on FB1 and hepatotoxicity in humans.  In addition, 
there is conflicting data on FB1 induced apoptosis.  An integration of epigenetic and 
cellular death machanisms is not common in toxicology research.  This study aimed to 
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ABSTRACT 
Fumonisin B1 (FB1), a common mycotoxin contaminant of maize, is known to inhibit 
sphingolipid biosynthesis and has been implicated in cancer promoting activity in 
animals and humans. FB1 disrupts DNA methylation and chromatin modifications in 
human hepatoma (HepG2) cells. We investigated the effect of FB1 on enzymes, DNA 
methyltransferases and demethylases, involved in chromatin maintenance and gross 
changes in structural integrity of DNA in HepG2 cells.  We measured: (i) the 
expression of 84 key genes encoding enzymes known to modify genomic DNA and 
histones (super array and qPCR); (ii) protein expression of DNA methyltransferases 
(DNMT1, DNMT3A and DNMT3B) and the major demethylase (MBD2) (western 
blotting); (iii) degree of DNA methylation by FACS using anti-5-MeCyt and (iv) 
DNA migration (single cell gel electrophoresis).   FB1 significantly decreased the 
methyltransferase activities of DNMT1, DNMT3A and DNMT 3B, and significantly 
up regulated the demethylases (MBD2 expression and activity, and KDM5B and 
KDM5C expression).   FACS data showed FB1 significantly increased DNA 
hypomethylation and resulted in gross changes in structural DNA as evidenced by the 
Comet assay. We conclude that FB1 induces global DNA hypomethylation and 
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1. Introduction 
Fumonisin B1 (FB1), a mycotoxin produced by the ubiquitous soil fungus Fusarium 
verticilliodes, is the most common fungal contaminant of maize worldwide (Domijan 
et al. 2007; Gelderblom and Marasas 2012; Marasas 2001). FB1 has been implicated 
in cancer promoting activity in the liver and kidney in animals and humans (Domijan 
et al. 2007; Gelderblom et al. 2008; Soriano et al. 2005; Stoev et al. 2012; Voss et al. 
2006). 
Fumonisin B1 is a diester of propane-1,2,3-tricarboxylic acid (TCA) and 2 
amino-12,16-dimethyl-3,5,10,14,15-pentahydroxyeicosane, in which the C14 and C15 
hydroxyl groups are esterified with a terminal carboxyl group of TCA (Bezuidenhout 
et al. 1988; Soriano et al. 2005). This toxin has structural similarity to the sphingoid 
bases sphinganine and sphingosine.  FB1 disrupts sphingolipid biosynthesis by 
competitively inhibiting ceramide synthase (N-acetyltransferase), resulting in 
accumulated levels of sphingoid bases (Soriano et al. 2005; Voss et al. 2006). This 
toxic action of FB1 affects cellular processes such as cell growth and differentiation, 
apoptosis and oxidative stress (Soriano et al. 2005). FB1 has been shown to be 
carcinogenic in both the liver and kidney due to disruption of sphingolipid 
biosynthesis (Voss et al. 2002).  
Because FB1 is a highly polar toxin, it traverses the plasma membrane, probably via 
amino acid transporters, and interacts with subcellular structures and disrupts cellular 
function (Bezuidenhout et al. 1988). It is resistant to conditions normally used in food 
processing and therefore poses a significant hazard to human and animal health (Scott 
2012). It is estimated that the average daily intake of FB1 may range between 12-
140µg, however in geographical regions where maize is the staple diet (e.g., South 
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Africa), this may increase up to 2500µg (WHO 2012). Many types of pathologies, 
which appear to be both species and tissue specific, have been associated with 
exposure to FB1 (WHO 2012). 
Animal studies have shown that FB1 is a hepatocarcinogen and epidemiological 
evidence suggests that it may be an aetiological agent in human oesophageal cancer 
(Alizadeh et al. 2012; Chu and Li 1994; Sun et al. 2007; Yoshizawa et al. 1994). 
While the cytotoxic mechanism of FB1 is attributed to its disruption of sphingolipid 
metabolism, the underlying mechanisms of its cancer initiating/promoting properties 
are unknown.  Several studies in rodents have shown that FB1 promotes pre-neoplastic 
lesions in the liver, suggesting a role for FB1-induced genotoxicity (Domijan et al. 
2008; Gelderblom et al. 2008; Karuna and Rao 2013).  
Molecular dynamic simulations of FB1 show that the toxin adopts multiple long-lived 
dielectric conformations when in solution, and can therefore interact with 
macromolecules within the cell (Momany and Dombrink-Kurtzman 2001). It is likely 
that FB1 may interact with DNA bases, or structural components of chromatin, 
thereby promoting a pre-neoplastic phenotype; however there is currently no 
experimental evidence to support this. 
The integrity of chromatin structure is strictly maintained by a repertoire of enzymes, 
which can directly modify DNA bases by methylation (methylases/demethylases) or 
structural components such as histones (acetylases/deacetylases).   DNA methylation 
is a chemical modification of DNA involved in regulation of gene expression (Issa et 
al. 1993). A hallmark of cancer is aberrant DNA methylation: (i) hypermethylation of 
tumour suppressor genes, (ii) aberrant expression of DNA methyltransferase 1 
(DNMT1 and other DNMTs) and methyl binding proteins (e.g., MBD2), as well as 
(iii) hypomethylation of unique genes (Baylin et al. 2001; Ehrlich 2002; Issa et al. 
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1993; Stefanska et al. 2013).  DNA methylation is an epigenetic mechanism involved 
in transcriptional silencing of genes.  Methyl-CpG binding domain protein 2 (MBD2), 
a member of the MBD protein family, binds to methylated promoter CpG islands and 
acts as a methylation-dependent transcriptional repressor (Berger and Bird 2005).  
Both DNA methylation and chromatin modifications have been associated with 
tumourigenesis, few studies have investigated the role of FB1 in liver cancer 
progression. This study investigated the effect of FB1 on enzymes involved in 
chromatin maintenance and gross changes in structural integrity of DNA in HepG2 
cells. 
2. Materials and Methods 
2.1 Treatment  
Approximately 1.5 x106 HepG2 cells were plated in sterile 25cm3 flasks in complete 
culture media [Eagle’s minimum essential medium, 10% foetal calf serum, 1% L-
Glutamine and 1% penstrepfungizone] and incubated overnight at 37oC in a 
humidified incubator with a supply of 5% CO2. A stock solution of 5mM FB1 was 
prepared in 0.1M phosphate buffered saline (PBS). HepG2 cells were treated with a 
range (0- 1000µM) of concentrations of FB1. A dose dependent decline in HepG2 cell 
viability was observed and an IC50 value of 200µM was determined (Addendum A: 
Table 1 and Figure 1). For all subsequent experiments, cells were treated with 200µM 
FB1 in a final volume of 5ml/ 25cm3 flasks and corresponding control flasks were 
maintained for 24hr (37oC, 5% CO2). All treatments were done in triplicate. A second 
set of experiments was performed (in triplicate with another batch of cultured cells) to 
check for reproducibility. 
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2.2 Transcriptional profiling of chromatin modifying enzymes    
Following FB1 treatment cells were rinsed (0.1M PBS) and 500µl 0.1M PBS was 
added to each flask. An aliquot of 500µl Tri Reagent® Solution (Ambion, USA) was 
added to each flask for isolation of RNA. Total RNA was isolated using the RNeasy 
Isolation Kit (Qiagen, USA) as per standard methods and quantified 
spectrophotometrically using a Nanodrop 2000.  cDNA was synthesised using the 
RT2 First-Stand Kit (Qiagen, USA) and the Epigenetic Chromatin Modification 
Enzymes PCR array (PAHS-085Z, Qiagen, USA) was used to profile expression of 
84 key genes encoding enzymes known or predicted to modify genomic DNA and 
histones to regulate chromatin accessibility and therefore gene expression. 
2.3 Western blot  
Isolated protein samples (HepG2 crude protein extract standardized to 1mg/ml) were 
denatured by boiling for 10min with a 1:1 dilution with 1× Laemmli sample buffer 
(0.375M Tris–HCl pH 6.8; 10%, w/v SDS; 3%, v/v glycerol; 0.2%, w/v bromophenol 
blue; 12% β-mercaptoethanol in dH2O). For each sample, 100µg of total protein was 
loaded on a 10% polyacrylamide gel, run at 150V. Transfer onto nitrocellulose 
membrane was conducted at 350mA for 1hr. Membranes were blocked for 1hr with 
blocking buffer containing 5% non-fat dry milk in Tris buffered saline (TTBS, 25mM 
Tris pH 7.6, 150mM NaCl, 0.05% Tween 20).  
Membranes were probed overnight at 4°C with anti-DNMT1, anti-DNMT3A, anti-
DNMT3B, anti-MBD2 (Santa Cruz Biotechnology, USA) and anti-β actin (Sigma, 
USA) diluted to 1:500 in 1% BSA in TTBS.  A horseradish peroxidase-conjugated 
secondary antibody diluted to 1:10 000 in 1% bovine serum albumin (BSA) in TTBS 
was used to allow detection of appropriate bands using LumiGLO® 
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Chemiluminescent Substrate Kit (KPL). Images were captured on the Alliance 2.4 gel 
documentation system (UViTech, UK). All experiments were conducted at least thrice 
and blots were analysed using UViBand analysis software (UViTech, UK). 
2.4 DNA methylation analysis by Fluorescent-activated cell sorting (FACS)  
The degree of DNA methylation in FB1 treated and control HepG2 cells was assessed 
via intracellular probing using flow cytometry. Cells (1x106, in triplicate) were fixed 
in Fix & Perm solution Medium A (Caltag, Germany) (room temperature (RT), 
30min, in the dark) and pelleted (10 000xg, 3min). Cells were resuspended in and 
permeabilised with Fix and Perm Medium B (Caltag, Germany) which contained the 
monoclonal anti-5-MeCyt (1:100, RT, 30min, in the dark). A 1ml aliquot of wash 
buffer (0.1M PBS, 5% foetal bovine serum, 1% sodium azide) was added to each 
sample and cells were pelleted (10 000xg, 3min). Cells were resuspended in Medium 
B containing APC-conjugated goat anti-mouse secondary antibody (1:100, 15min, 
RT, in the dark).  
A 1ml aliquot of wash buffer (0.1M PBS, 5% foetal bovine serum, 1% sodium azide) 
was added to each sample and cells were pelleted (10 000xg, 3min). Cells were 
resuspended in 300µl sheath fluid and transferred to polystyrene cytometry tubes. All 
experiments were done in duplicate.  Flow cytometry data from stained cells (25 000 
events) was obtained using a FACSCalibur (BD Biosciences, USA) flow cytometer 
with CellQuest PRO v4.02 software (BD Biosciences, USA). Cells were gated to 
exclude debris using FlowJo v7.1 software (Tree Star, Inc).  (Addendum B- Figures 2 
and 3). 
2.5 Single cell gel electrophoresis assay 
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The effect of FB1 on DNA migration/damage was determined with the comet assay. 
Briefly, following treatment of cells (20 000 cells/well) in a 6-well plate, supernatants 
were removed and cells were trypsinized. Three slides (for FB1 treatment and 
controls) were prepared as the first layer of 1% low melting point agarose (LMPA, 
37ºC), second layer of 25µl of cells (20 000) from the treated and control samples 
with 175µl of 0.5% LMPA (37ºC) and third layer of 0.5% LMPA (37ºC) covered the 
slides.  
After solidification, the slides were then submerged in cold lysing solution [2.5M 
NaCl, 100mM EDTA, 1% Triton X-100, 10mM Tris (pH 10), 10% DMSO] and 
incubated (4ºC, 1hr). Following incubation the slides were placed in electrophoresis 
buffer [300mM NaOH, 1mM Na2EDTA (pH 13)] for 20min and thereafter subjected 
to electrophoresis (25V, 35min, RT) using Bio-Rad compact power supply. The slides 
were then washed 3 times with neutralisation buffer [0.4M Tris (pH 7.4)] for 5min 
each.  
The slides were stained overnight (4ºC) with 40µl ethidium bromide (EtBr) and 
viewed with a fluorescent microscope (Olympus IXSI inverted microscope with 510-
560nm excitation and 590nm emission filters). Images of 50 cells and comets were 
captured per treatment and the comet tail lengths were measured using Soft imaging 
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3. Results 
3.1 Fumonisin B1 decreased expression of DNA methyltransferases and 
concomitantly increased expression of DNA demethylases 
We screened human hepatoma (HepG2) cells treated with FB1 for transcriptomic 
changes in enzymes known to be involved in chromatin modification using qPCR 
arrays (Qiagen). Cluster gram analysis showed notable transcriptional changes in 
enzymes that regulate DNA methyl metabolism in FB1 treated HepG2 cells compared 
to controls (Figure 3.1A). Fold regulation analyses showed that FB1 treatment 
significantly decreased the expression of DNA methyltransferases specifically, 
(DNMT1, DNMT3A and DNMT3B, 2 fold, 6 fold and 4 fold decreases respectively) in 
HepG2 cells. Conversely, expression of DNA demethylases KDM5B (2.5 fold 
increase), KDM5C (4 fold increase) and MBD2 was significantly increased. The most 
significant FB1-induced increase in expression was observed for MBD2 (7.7 fold 
increase in transcript levels) (Figure 3.1B/C).  
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Figure 3.1 Fumonisin B1 induced changes in expression levels of DNA 
methyltransferases and DNA demethylases in HepG2 cells. (A) Cluster gram analysis 
and (B) fold regulation analysis shows down-regulation of DNA methyltransferases 
and concomitant up-regulation of MBD2 and DNA demethylases in response to FB1. 
*p<0.005 (One way ANOVA). (C) Relative changes in expression in control vs. 200 
µM FB1 treated HepG2 cells. 
3.2 Fumonisin B1 decreased protein expression of DNA methyltransferases and 
increased expression of MBD2  
We next investigated whether the transcriptional fluxes observed in the gene 
expression studies were related to absolute changes in protein levels. Western-blot 
experiments and digital densitometry confirmed that levels of DNMT1 (1.6-fold), 
DNMT3A (2.4-fold) and DNMT3B (1.7-fold) were decreased in HepG2 cells in 
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response to the toxic insult by FB1. The data also showed a change in MBD2 protein 
levels (1.2-fold change) as a result of FB1 exposure in HepG2 cells (Figure 3.2).  
 
Figure 3.2 Fumonisin B1 decreased expression of DNA methyltransferases and 
increased MBD2 protein expression as shown by western blots (A). Data represented 
as a fold change relative to the control (B).  Non-parametric Mann Whitney Test. 
(DNMT1 - *p < 0.0286; DNMT3A- *p < 0.0286; DNMT3B - *p < 0.0286; MBD2 - 
**p < 0.0079). 
3.3 Fumonisin B1 induced global DNA hypomethylation in HepG2 cells 
After treatment with FB1 we enumerated the number of HepG2 cells positive for 5-
methylcytosine, a marker used to monitor global DNA methylation. The data showed 
that FB1 induced global DNA hypomethylation in HepG2 cells at 200µM (Figure 
3.3A). There was a significant reduction in the number of FB1 treated HepG2 cells 
positive for 5-methylcytosine (Figure 3.3B). 
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Figure 3.3 Fumonisin B1 induced global DNA hypomethylation in HepG2 cells as 
assessed using flow cytometry (A).  Data represented as a fold change compared to 
control (B). 
3.4 Fumonisin B1 increased DNA migration in HepG2 cells 
Following treatment with FB1 (200µM) we assessed DNA migration in HepG2 cells 
using the comet assay. The data showed that FB1 induced a significantly higher 
degree of DNA migration (2.57 µm ± 0.02 µm vs. control: 0.812 µm ± 0.01 µm, 
p=0.0022, Figure 3.4A/B). 
 
Figure 3.4 Fumonisin B1 increased DNA comet tails in HepG2 cells (A).  
Comparison of comet tail lengths (in µM) between control and Fumonisin B1 treated 
cells (B). 
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4. Discussion 
The canonical mechanism of action associated with FB1 is disruption of sphingolipid 
biosynthesis by inhibition of ceramide synthase. There are various reports that 
confirm this phenomenon and have established that FB1 dysregulation of sphingolipid 
metabolism strongly correlates with both human and veterinary pathogenesis.  In vitro 
evidence suggests that a decreased bioavailability of sphingoid bases will tend toward 
a cytotoxic phenotype. In the context of FB1 therefore, disruption of sphingolipid 
metabolism may not fully explain the proliferative and ultimately oncogenic 
properties of this food borne mycotoxin. In this report, we present evidence that FB1 
induces global DNA hypomethylation in human hepatoma cells and suggests that the 
mechanism is by altering the balance of DNA methylases/demethylases, thereby 
disrupting the structural integrity of DNA. 
Our data strongly suggests that the mechanism of FB1-induced DNA hypomethylation 
is related to modulation of key enzymes critical for the maintenance of an integral 
epigenetic landscape.  This report clearly shows that FB1 leads to chromatin 
instability and aberrant transcriptional activation. FB1 significantly decreased the 
expression of DNA methyltransferases (DNMT1, DNMT3A and DNMT3B) and 
concomitantly significantly increased expression of MBD2 (a demethylase) and the 
histone demethylases (KDM5B and KDM5C). Decreased DNA methyltransferase 
(DNMT1, DNMT3A and DNMT3B) and increased demethylase (MBD2) protein 
expression was further confirmed with western blot analysis.  Demethylation in 
cancer is common and involves hypomethylation of repetitive sequences, although its 
role in genes encoding proteins still remains to be elucidated. However, DNMT 
inhibitors were shown to cause DNA demethylation that led to the induction of 
prometastatic genes and metastasis suggesting a possible role for hypomethylation in 
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cancer metastasis (Pakneshan et al. 2004; Shteper et al. 2003).  MBD2, a major 
demethylase, is essential for expression and demethylation of the prometastatic genes 
urokinase-type plasminogen activator (PLAU) and matrix metalloproteinase 2 
(MMP2) (Pakneshan et al. 2004; Shukeir et al. 2006).  MBD2 inhibition by antisense 
oligonucleotides silenced both these genes and resulted in inhibition of invasiveness 
and metastasis of breast and prostate cancer cell lines (Pakneshan et al. 2004).  
Furthermore, Stefanska et al. (2011) demonstrated that knock down of MBD2 in 
HepG2, SkHep1 (liver adenocarcinoma cell line) and NorHep (human untransformed 
hepatocytes) cells confirmed that hypomethylation in liver cancer targets promoters of 
specific genes encoding functional pathways required for growth and invasion.  
However, even a partial reversal of this process in the liver cell lines used resulted in 
tumour growth and invasiveness in the liver cancer cells but not the normal liver cells 
(Stefanska et al. 2011). 
In our study, FB1 significantly up regulated both MBD2 transcript and protein 
expression by 7.7- and 3.5- fold respectively strongly suggesting that FB1 may play a 
causal role in cellular transformation and invasiveness in HepG2 cells.  MBD2 was 
previously shown to act as both a transcriptional repressor and an activator of gene 
expression by promoting demethylation of its target-activated genes (Detich et al. 
2002; Stefanska et al. 2013).  Our data shows that FB1 upsets the balance of enzymes 
necessary for proper regulation of DNA methylation.  While demethylation is 
necessary for transcription, if it occurs on a global scale it will result in large stretches 
of “loose” DNA, as observed by the increased comet tail lengths induced by FB1. This 
is the first report that shows FB1 (a type 2B carcinogen) perturbs epigenetic gene 
regulation and may be involved in tumourigenesis. 
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A study on depletion of MBD2 in HepG2 cells not only resulted in the silencing of at 
least 15 genes induced in liver cancer, but also blocked the transformation and 
invasive properties of the cell (Stefanska et al. 2011).  These authors concluded that 
MBD2 was a master regulator of some of the genes activated in liver cancer but also 
that hypomethylation and activation of this set of genes played a causal role in cancer, 
particularly cancer metastasis (Stefanska et al. 2011).  Our data is in agreement with 
this study as FB1 significantly increased the expression of both MBD2 (7.7 fold) and 
MBD2 (3.5 fold), implicating FB1 as a hepatocarcinogen.  Further our results confirm 
that FB1 induces global DNA hypomethylation in HepG2 cells as evidenced by a 
decreased number of cells staining for 5-methylcytosine. 
FB1 also significantly increased the expression of two histone demethylase genes 
KDM5B and KDM5C. Both demethylases are members of the Jumonji (JmjC) family 
of proteins that catalyse the demethylation of tri- and dimethylated lysines (Cloos et 
al. 2008; Cloos et al. 2006).  They specifically act on tri- and dimethylated lysine 4 on 
histone H3 (H3K4) (only found at transcribed genes) and are associated to 
euchromatin and active transcription (Cloos et al. 2008).  Trimethylated H3K4 is 
highly enriched around transcriptional start sites whilst dimethylated H3K4 is present 
throughout the coding region of transcribed genes (Bernstein et al. 2005).  KDM5B is 
regulated by the oncogene c-ErbB2 and is highly expressed in ductal breast 
carcinomas and is associated with the malignant phenotype in breast (Barrett et al. 
2002).  In addition to its role in promoting cancer, KDM5B is needed for the 
proliferation of MCF-7 breast cancer cell line and tumour growth of mammary 
carcinoma cells in nude mice (Yamane et al. 2007). KDM5B target genes in breast 
cancer proliferation have been identified as BRCA 1, CAV 1 and HOXA5 (Yamane et 
al. 2007).  In our study, FB1 increased KDM5B and KDM5C expression in liver 
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HepG2 cells that will result in increased H3K4Me3/Me2 demethylation. A 
consequence of this increased H3K4 demethylation will disrupt its role as a 
transcriptional repressor. 
5. Conclusion 
In conclusion, our results show that FB1 induces global DNA hypomethylation (by 
downregulating DNA methyltransferases and upregulating MBD2) and histone 
demethylation in human hepatoma cells that causes chromatin instability and may 
lead to liver tumourigenesis.  
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ABSTRACT 
Fumonisin B1 (FB1), a common mycotoxin contaminant of maize, is known to inhibit 
sphingolipid biosynthesis and has been implicated in hepatocellular carcinoma 
promoting activity in humans and animals. MicroRNAs (miRNA) are small 
noncoding RNAs that regulate gene expression via translational repression. Human 
cytochrome P450 (CYP1B1) is highly expressed in oestrogen target tissues and 
catalyzes the metabolic activation of many procarcinogens.  The aim of our study was 
to investigate the effect of FB1 on miR-27b suppression and its effect on CYP1B1 
modulation in a human hepatoma cell line (HepG2).  MiR27b and CYP1B1 
expressions were evaluated in HepG2 cells by quantitative PCR. In order to directly 
assess the effect of miR-27b on CYP1B1 mRNA levels, cells were transfected with 
the mimic to miR-27b. CYP1B1 protein expression was measured using western blot.  
FB1 significantly down-regulated (11 fold) expression of miR-27b in HepG2 cells; 
whilst CYP1B1 mRNA and protein expression was significantly up-regulated by 1.8 
fold and 2.6 fold respectively.  CYP1B1 is post-transcriptionally regulated by miR-
27b after HepG2 exposure to FB1. FB1- induced modulation of miR-27b in hepatic 
cells may be an additional mode of hepatic neoplastic transformation. 
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 1. INTRODUCTION 
Fusarium verticilloides, a ubiquitous soil fungus and common contaminant of corn 
worldwide, produces the carcinogen fumonisin B1 (FB1) that is responsible for a wide 
range of species-specific toxicoses (Norred et al. 1998).  FB1, a structural analogue of 
sphingoid bases, is implicated in cancer promotion as it disrupts sphingolipid, 
phospholipid and fatty acid metabolism, which play a major role in the modulation of 
apoptosis and cell proliferation pathways (Gelderblom and Marasas 2012).  An 
elevation of free sphingoid bases by FB1 can induce apoptosis, whereas production of 
sphingosine-1-phosphate or inhibitors of ceramide biosynthesis can also inhibit 
apoptosis (Norred et al. 1998). Chronic feeding of animals with FB1 caused liver 
cancer in mice and rats (Howard et al. 2001).  At present little is known about FB1 
genotoxicity however, it is known that FB1 induces necrosis as well as apoptosis in 
the liver (Gelderblom and Marasas 2012). 
MicroRNAs (miRNA) are small non-coding RNAs regulating the expression of genes 
involved in various biological processes including cell proliferation and apoptosis 
(Ambros 2004).  Mature functional miRNAs (approximately 22 nucleotides in length) 
generated from long primary miRNA transcripts, control gene expression at the post-
transcriptional level by either degrading or repressing target mRNAs.  MiRNAs are 
thus selected gene regulatory molecules with each cell type likely to have a specific 
miRNA milieu to control gene expression (Chen 2005). The functional miRNAs have 
been predicted to regulate expression of approximately 30% of all human genes 
(Lewis et al. 2005). MiRNAs play an important role in coordinating many cellular 
processes such as regulating apoptosis, proliferation, differentiation, development and 
metabolism (Gusev 2008; Maziere and Enright 2007). 
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Some miRNAs expressed in cancer were found to regulate the expression of 
signalling molecules such as cytokines, growth factors, transcription factors and both 
pro- and anti-apoptotic genes; whilst some miRNAs may function as tumor 
suppressors or conversely oncogenes in cells (Calin and Croce 2006).  MiRNAs may 
therefore be one of the key regulators of tumourigenesis.   
Tsuchiya et al., (2006) found that cytochrome P450 (CYP1B1), a superfamily of drug 
metabolizing enzymes, was a target of miR-27b (Tsuchiya et al. 2006).  CYP1B1, a 
highly expressed enzyme in oestrogen target tissues, catalyzes the activation of 
various procarcinogens and promutagens, polycyclic aromatic hydrocarbons and aryl 
amines (Shimada et al. 1996) and 17β-estradiol (Lee et al. 2003).  In addition 
CYP1B1 is highly expressed in cancerous tissues (e.g. breast cancer) and a near-
perfect matching sequence was identified with miR-27b in the 3’-untranslated region 
(UTR) of CYP1B1 (Tsuchiya et al. 2006).  It was concluded that CYP1B1 was post-
transcriptionally regulated by miR-27b and that the expression level of miR-27b was 
decreased accompanied by high levels of CYP1B1 in the cancerous liver tissue 
(Tsuchiya et al. 2006). 
In response to noxious stimulation by FB1, and as a result of aberrant gene expression, 
cells may alter their normal miRNA profiles and create a micro-environment which 
facilitates carcinogenesis. This toxin is a potent liver carcinogen, however there is 
little consensus on the precise mechanism of neoplastic transformation. The effect of 
FB1 on miRNA has not been previously investigated and it is likely that cells may 
change their miRNA milieu in response to FB1.  In this study we screened for changes 
in miRNA expression profiles in human hepatoma cells (HepG2) following exposure 
to FB1. Interestingly, we show that FB1 induced significant changes in miR-27b 
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expression and in turn modulates CYP1B1 expression. We suggest that FB1- induced 
modulation of miR-27b in hepatic cells is an additional mode of hepatic neoplastic 
transformation. 
2. MATERIALS AND METHODS 
2.1 Treatment  
Approximately 1.5 x106 HepG2 cells were plated in sterile 25cm3 flasks in complete 
culture media [Eagle’s minimum essential medium, 10% foetal calf serum, 1% L-
Glutamine and 1% penstrep-fungizone] and incubated overnight at 37oC in a 
humidified incubator with a supply of 5% CO2. A stock solution of 5mM FB1 was 
prepared in 0.1M phosphate buffered saline (PBS). HepG2 cells were treated with a 
range (0- 1000µM) of concentrations of FB1. A dose dependent decline in HepG2 cell 
viability was observed and an IC50 value of 200µM was determined (data not 
presented). Cells were then treated with 200µM FB1 in a final volume of 5ml/ 25cm3 
flasks and corresponding control flasks were maintained for 24h (37oC, 5% CO2). All 
treatments were done in triplicate. 
2.2 Quantitative PCR array based profiling of microRNA  
Following FB1 treatment cells were rinsed (0.1M PBS) and 500µl 0.1M PBS was 
added to each flask. An aliquot of 500µl Tri Reagent® Solution (Ambion, USA) was 
added to each flask for isolation of RNA. Total RNA was isolated using the RNeasy 
Isolation Kit (Qiagen, USA) as per standard methods and quantified using a Nanodrop 
2000.  Copy DNA (cDNA) was synthesised using the miScript II RT kit (Qiagen, 
USA) and the miScript miRNA PCR Array Human miFinder (MIHS-001Z, Qiagen, 
USA) which contains 84 mature miRNA-specific primers. 
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2.3 Statistical analysis and selection of significant miRNA  
Data was normalised using U6 small RNA expression.  Difference in miRNA 
expression was determined by fold change analysis using the 2-ΔΔCt method (Livak and 
Schmittgen 2001).  To stringently select miRNAs significantly up- or down-regulated 
in FB1 treated cells, a significance of analysis of microarray (SAM) strategy was used.  
Significant (p<0.05) deviation of residuals from normal distribution was used to 
identify miRNAs of interest.  Data was analysed with Microsoft excel (2011) Statplus 
plug-in and R. 
2.4 Computational analysis of miRNA targets 
Pathway analysis was conducted by first identifying miRNA targets using the 
Targetscan and Miranda algorithms and thereafter, scanning for ontological 
enrichment in the KEGG database. 
2.5 Transfection of HepG2 cells with miR-27b mimic 
In order to directly assess the effect of miR-27b on CYP1B1 mRNA levels, cells were 
transfected with the mimic (Syn-hsa-miR-27b, MYS0000419, Qiagen, USA) to miR-
27b. Briefly, HepG2 cells were seeded at a density of 400 000 cells/well in a 6-well 
plate and allowed to adhere for 24h (37oC, 5% CO2) until 80% confluent. Lyophilized 
miRNA mimic (5nmol) was reconstituted to 20µM in nuclease free water. For the 
transfection, 10µl miRNA mimic was added to medium without serum, proteins, or 
antibiotics to a total volume of 60µl to which 2µl of HiPerFect Reagent (Qiagen, 
USA) was added and mixed by reverse-pipetting. Samples were then incubated for 
15min (room temperature) to allow complex formation. During this time CCM 
(complete culture medium) was gently aspirated from the cells and 1940µl fresh CCM 
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was added such that the final concentration of mimic per well was 50nM. The 
transfection complex was added in a drop-wise fashion into the appropriate well with 
gentle swirling of the plate to ensure uniform distribution. An untreated control and a 
200µM FB1 treatment were included on the plate. All treatments were then incubated 
for 24h (37oC, 5% CO2) and utilized for RNA isolation. 
2.6  Quantification of CYP1B1 mRNA levels  
To quantify CYP1B1 qPCR was performed. Total RNA was first isolated from 
control and treated cells by adding 500µl Tri reagent (Am9738) as per manufacturer’s 
guidelines. Thereafter, RNA was quantified (Nanodrop 2000) and standardised to 
100ng/µl. RNA was reverse transcribed by reverse transcriptase into cDNA using the 
RT2 First Strand Kit (SABiosciences, C-03, USA) as per manufacturer’s instructions. 
Briefly, a 20µl reaction was prepared by adding 10µl genomic DNA (gDNA) 
elimination mixture (Total RNA, 5× gDNA elimination buffer, H2O) to 10µl of RT 
cocktail (5× RT buffer 3, primer and external control mix, RT enzyme mix, H2O). 
The reaction was then subjected to 42°C (15min) and 95°C (5min) (GeneAmp® PCR 
System 9700, Applied Biosystems, USA) to obtain cDNA. Quantitative PCR was 
used to determine mRNA expression using RT2 SYBR® Green qPCR Master Mix 
(SABiosciences, USA). A 25µl reaction consisting of 12.5µl iQ™ SYBR® green 
supermix (cat. no. 170–8880), 8.5µl nuclease-free water, 2µl cDNA, and 1µl sense 
and anti-sense primers for CYP1B1 (1B1DSF 5’- GCCACTATCACTGACATCT-3’, 
1B1DSR 5’-CTTGCCTCTTGCTTCTTATT-3’), 10mM, Inqaba Biotechnical 
Industries™, South Africa) were used. The mRNA expression was compared and 
normalised to a housekeeping gene, GAPDH (sense: 3’-
CAACAGCCTCAAGATCATCAGC-5’; anti-sense: 3’-
TGAGTCCTTCCACGATACCAAAG-5’). 
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The reaction was subjected to an initial denaturation (95°C, 10min). It was followed 
by 40 cycles of denaturation (95°C, 15s), annealing at 57°C, 40s; and extension 
(72°C, 30s) (CFX Real-Time PCR detector, Bio-Rad, USA). The data was analyzed 
using CFX analysis software V3.0, Bio-Rad. The mRNA expression was determined 
using the method described by Livak and Schmittgen (2001) (Livak and Schmittgen 
2001) and is represented as fold changes relative to the control. 
2.7  Quantification of CYP1B1 protein levels 
Samples (HepG2 crude protein extract standardized to 1mg/ml) were denatured by 
boiling for 10min with a 1:1 dilution with 1× Laemmli sample buffer (0.375 M Tris–
HCl pH 6.8; 10%, w/v SDS; 3%, v/v glycerol; 0.2%, w/v bromophenol blue; 12% β-
mercaptoethanol in dH2O). For each sample, 100µg of total protein was loaded on a 
10% polyacrylamide gel, run at 150V. Transfer onto PVDF membrane was conducted 
at 350mA for 1h. Membranes were blocked for 1h with blocking buffer containing 
5% non-fat dry milk TTBS (25mM Tris pH 7.6, 150mM NaCl, 0.05% Tween 20). 
Membranes were probed overnight at 4°C with anti-CYP1B1 antibody (PA5-28040, 
Thermo-Scientific, USA) and anti-β actin antibody (A3854, Sigma, USA) diluted to 
1:500 in 1% BSA in TTBS.  A horseradish peroxidase-conjugated secondary antibody 
diluted to 1:10 000 in 1% BSA in TTBS was used to allow detection of appropriate 
bands using LumiGLO® Chemiluminescent Substrate Kit (KPL). Images were 
captured on the Alliance 2.4 gel documentation system (UviTech, UK). All 
experiments were conducted at least thrice and blots were analysed using UViBand 
analysis software (UviTech, UK). 
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3.  RESULTS 
3.1 MicroRNA profiles in Fumonisin B1 treated HepG2 cells 
MiRNA profiling showed that FB1 induced differential regulation of miRNAs in 
HepG2 cells.  Expression profile heat map shows robust signals from control and 
treated cells (Figure 4.1A).  This indicated good data integrity and that dataset is 
suitable to mine for candidate miRNAs that may be differentially regulated by FB1 
treatment. Each point in the expression profile plot (Figure 4.1B) represents a single 
miRNA species with total coverage of 84 unique miRNAs. This analysis shows that 
miRNA expression profiles in both control and FB1 treated cells track similarly which 
indicates that the majority of miRNA expression in HepG2 cells remain unchanged 
upon exposure to FB1.  However, four peaks/miRNAs in FB1 treated cells and one 
peak/miRNA in control track with higher intensity, suggesting that these miRNAs 
may be differentially regulated in the context of FB1.   
 
	   81	  
 
 
Figure 4.1 MiRNA profiles in Fumonisin B1 treated HepG2 cells. A: 
Expression profile heat map. B: Relative expression profile plot of miRNAs in control 
and FB1 treated HepG2 cells. 
3.2 Cluster analysis of miRNA expression in Fumonisin B1 treated HepG2 cells 
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To further examine discrete differences in miRNA expression induced by FB1, we 
used hierarchical cluster analysis. miRNA expression was first clustered by Euclidian 
distance and then by linkage analysis. We found that five miRNAs were down 
regulated (miR-135b, miR-181d, miR-27a, miR-27b and miR-30c) (Figure 4.2A). 
Relative expression profile of top five clustered miRNAs shows that of these, miR-
27b is most significantly decreased upon treatment with FB1 (Figure 4.2B). 
 
Figure 4.2 Hierarchical cluster analysis of miRNA expression in Fumonisin 
B1 treated HepG2 cells.  A: Heat map shows a descending ordered list of significant 
miR clusters in control cells.  B: miR-27b expression is dysregulated by FB1 treated 
cells. 
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3.3 Fumonisin B1 down-regulates miR-27b 
Unperturbed HepG2 cells express high levels of miR-27b however, exposure to FB1 
significantly decreased miR-27b by over 10 fold (Figures 4.3A and 4.3B). 
Independent experiments confirmed that FB1 represses miR-27b reproducibly and 
significantly (Figure 4.4). 
 
Figure 4.3 miR-27b expression is dysregulated by Fumonisin B1.  A:  
Expression vs fold change analysis shows that miR-27b is expressed at high levels in 
control HepG2 cells and suggests that FB1 represses miR-27b.  B: In depth evaluation 
of relative expression shows that miR-27b is decreased by more than 10 fold in 
HepG2 cells upon treatment with FB1. 
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Figure 4.4 Fumonisin B1 decreased expression of miRNA-27b. Data 
represented as a fold change relative to the control.  Non-parametric Mann Whitney 
Test. (**p < 0.001; ***p < 0.0001).  
3.4 Target prediction of miR-27b 
The standard miRNA target prediction tools were used to search for potential 
candidates genes that may be transcriptionally regulated by miR-27b.  All tools 
returned extensive lists (Table 4.1) of possible targets for miR-27b. Of these however, 
the 3’UTR of CYP1B1 has a near perfect complementarity to the seed sequence of 
miR-27b (Figure 4.5A) Furthermore, apart from Notch1, CYP1B1 remains the only 
experimentally validated target for miR-27b to date (Biyashev et al. 2012). Taking 
into account the role of cytochromes in liver metabolism, CYP1B1 is a likely target in 
this experimental context.  
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Table 4.1: Target prediction metrics for miR-27b 






3.5 Altered CYP1B1 mRNA levels by Fumonisin B1   
We investigated whether down-regulation of miR-27b by FB1 influenced mRNA 
levels of CYP1B1.  Quantitative PCR experiments confirmed that levels of CYP1B1 
were increased in HepG2 cells treated with FB1 (1.80-fold ± 0.03) compared to the 
control (1.00 ± 0.04). CYP1B1 levels were normalised in the presence of a miR-27b 
mimic confirming that the miR-27b – CYP1B1 axis is operational in this system and 
furthermore, can be modulated by FB1 (Figure 4.5B). 
3.6 Fumonisin B1 increases CYP1B1 protein expression  
We assessed the effect of FB1 on levels of CYP1B1 protein in HepG2 cells by 
western blotting. A significant 2.6-fold increase in CYP1B1 expression was found in 
FB1 treated cells following densitometry analysis of protein bands normalised to β-
actin (p<0.0001) (Figure 4.5C).   
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Figure 4.5 Fumonisin B1 modulates CYP1B1 expression. A: Sequence 
homology alignment between CYP1B1 mRNA and predicted target sequence of miR-
27b. B: FB1 increased expression of CYP1B1 mRNA. Data represented as a fold 
change relative to the control (**p < 0.001, Mann Whitney Test). C: Immuno-blot of 
CYP1B1.  CYP1B1 expression was highest in FB1 treated HepG2 cells. Data 
represented as relative band density normalised against β-actin (***p < 0.0001, 
Unpaired t-test). 
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4. DISCUSSION 
The current mechanism of action associated with FB1 is inhibition of ceramide 
synthase and the disruption of sphingolipid biosynthesis. The sphingolipid 
dysregulation by FB1 strongly correlates with mammalian pathogenesis, including 
cancer.  However, disruption of sphingolipid metabolism alone may not fully explain 
the proliferative and ultimately oncogenic properties of FB1. In this report, we present 
evidence that FB1 significantly down-regulates miR-27b and concomitantly up-
regulates both CYP1B1 mRNA and its protein expression in human hepatoma cells.  
This is the first study, to our knowledge, on miRNA and the food-borne hepatotoxin 
FB1.  CYP1B1 (an enzyme that catalyzes the conversion of procarcinogens and 
oestradiol) is strongly associated with mutagenesis and is found in high levels in 
many cancerous tissues (Cheung et al. 1999; Ragavan et al. 2004).   Specifically, 
CYP1B1 metabolises 17β-oestradiol (a known contributor to the growth and 
development of oestrogen-dependent cancers) (Lee et al. 2003).  Further, 4-
hydroxyoestradiol, a reactive metabolite formed by CYP1B1, is known to generate 
free radicals and that can cause DNA damage (Han and Liehr 1994; Newbold and 
Liehr 2000). We recently found that FB1 (200µM) induced global DNA 
hypomethylation in HepG2 cells by significantly decreasing the methyltransferase 
activities of DNMT1, DNMT3A and DNMT3B, and significantly up-regulated the 
activity of demthylase methyl binding protein (MBD2) (Chuturgoon AA et al. 2013). 
We concluded that FB1 induced global DNA hypomethylation and histone 
demethylation in human hepatoma cells by causing chromatin instability that leads to 
liver tumorigenesis. There is still come confusion regarding the selective expression 
of CYP1B1 in cancer as its mRNA is expressed in both cancer and normal cells and it 
was erroneously assumed that CYP1B1 protein expression would be the same 
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(McFadyen and Murray 2005).  McFadyen and Murray (2005) provided evidence for 
plausible mechanisms to explain the dislocation between CYP1B1 mRNA and protein 
expression in normal cells (McFadyen and Murray 2005).  In 2005 two different 
mechanisms of CYP1B1 regulation were proposed, with experimental evidence, 
showing extreme over-expression in cancer cells.  One suggestion was the 
transcriptional regulation by hypermethylation of the promoter/enhancer region of the 
CYP1B1 gene resulting in decreased mRNA expression in normal cells (Tokizane et 
al. 2005); whilst the second suggestion was post-transcriptional regulation by 
proteosomal degradation of CYP1B1 protein in normal cells, targeted through 
polyubiquitination, but not phosphorylation (Bandiera et al. 2005).  The most 
convincing post-transcriptional mechanism postulates that the over-expression of 
CYP1B1 in cancer cells because these cells are largely deficient of miRNA (miR-27b) 
which in normal cells inhibits the translation of CYP1B1 mRNA into protein 
(Tsuchiya et al. 2006). It is well known that miRNA expression is globally changed in 
cancerous tissue.  
After seven years since the Tsuchiya et al. (2006) study (Tsuchiya et al. 2006), we 
provide evidence to support the post-transcriptional modification of CYP1B1 mRNA 
and protein expression by miR-27b in hepatoma cells, albeit induced by the 
hepatotoxin FB1.  There is strong complementarity between 3’-UTR CYP1B1 mRNA 
transcript and the seed sequence of miR-27b (Figure 5A).  Increased expression and 
activity of CYP1B1 has been associated with mutagenesis and carcinogenesis.  We 
provide evidence that FB1 “induces” over-expression of both CYP1B1 mRNA and 
protein (Figures 5B and 5C).  Placing our evidence in context, the effect of FB1 on 
CYP1B1 may not be direct, but instead as a result of decreased repressive activity by 
miR-27b due to FB1 related decrease in miR-27b levels (Figure 6). 
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Figure 4.6 Fumonisin B1 regulation of CYP1B1 by modulation of miR-27b. 
In conclusion a significant inverse association was observed between the expression 
levels of miR-27b and CYP1B1 protein in HepG2 cells induced by FB1.  Thus, the 
decreased expression of miR-27b would be one of the causes of higher CYP1B1 
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Abstract 
Fumonisin B1 (FB1) is a mycotoxin produced by Fusarium sp., a common 
contaminant of maize. FB1 inhibits sphingolipid biosynthesis, alters 
sphingosine/sphinganine ratios and modifies cell survival and cell death processes at 
varying propensities at both species- and tissue-specific level. We investigated the 
effect of FB1 on the apoptotic pathway in human hepatoma (HepG2) cells.  We 
measured: (i) the level of cell proliferation and cell death mechanism of HepG2 cells 
(MTT assay, Annexin V and Propidium Iodide staining); (ii) initiator and executioner 
caspase activity (Luminometric enzyme activity assays); (iii) regulation of mRNA 
expression of pro- and anti- apoptotic molecules using an apoptosis array (qPCR) and 
(iv) levels of significantly altered apoptosis-related proteins (Western blotting) 
following a 24hr incubation. FB1 caused a dose-dependent decrease in cell viability 
with an inhibitory concentration for 50% of cell growth at 200µM. FACS data 
showed FB1 induced a 2.5-fold increase in Annexin V staining, however, caspase 
activity was not significantly influenced by the toxin. BIRC-8/ILP-2 was most 
significantly up regulated (8-fold) in the apoptosis array. ILP-2 protein levels were 
elevated (2.3-fold) with a corresponding decrease in Smac/DIABLO protein levels 
(1.7-fold). Further analysis showed a dose-dependent increase in BIRC-8/ILP-2 
mRNA and protein expression in HepG2 cells. We conclude that FB1 modulates 
apoptosis in a complex dose-dependent regulation of pro- and anti-apoptotic 
molecules. 
Keywords: 
Fumonisin B1; Apoptosis; BIRC-8; ILP-2; Liver cancer 
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1. Introduction 
Fumonisin B1 (FB1) is a carcinogenic mycotoxin produced by Fusarium verticilloides 
and F. proliferatum, a common worldwide fungal contaminant of corn (Marasas, 
2001).  Contamination of corn by FB1 is of concern as it causes various animal 
diseases and is found at high levels in corn-based products intended for human 
consumption (Shephard et al., 1996).  Elevated levels of FB1 in naturally 
contaminated corn has been associated with high incidences of human disease 
globally, namely, liver cancer in Japan (Ueno et al., 1997), oesophageal cancer in 
South Africa (Rheeder et al., 1992) and gastrointestinal cancers in China (Chu and Li, 
1994).  FB1 in itself is not mutagenic (Knasmuller et al., 1997). Rather, its cancer 
promoting activities in the liver is related to major changes in cellular biochemistry 
coupled with associated epigenetic changes (Chuturgoon et al., 2014a; Chuturgoon et 
al., 2014b).   
FB1 disrupts de novo sphingolipid biosynthesis by inhibiting ceramide synthase, thus 
preventing conversion of sphinganine to dihydroceramide and reacylation of 
sphingosine to ceramide (Wang et al., 1991).  This results in increased sphingoid 
bases and their 1-phosphate derivatives and decreased ceramides and complex 
sphingolipids (Merrill et al., 2001).  Slight variations in levels of sphingolipids can be 
perceived as cellular stress signals that can induce apoptosis. However, evidence 
shows that manipulation of ceramide levels by cancer cells render them resistant to 
cytotoxic agents that induce apoptosis. FB1 sphingolipid disruption can either induce 
or prevent apoptosis, depending on the cell type and the relative amounts of bioactive 
sphingolipid molecules (Desai et al., 2002). 
 
Early reports showed that FB1 induced apoptosis in several different mammalian cell 
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types (Ciacci-Zanella and Jones, 1999; Schmelz et al., 1998; Wang et al., 1996). 
However, studies on neoplastic African green monkey kidney cells (COS-7) 
demonstrated resistance to the apoptotic effects of FB1 compared to their normal 
counterparts, (CV-1) (Ciacci-Zanella et al., 1998; Wang et al., 1996). Additionally, 
murine or human leukemia cells do not undergo apoptosis when treated with FB1 
(Bose et al., 1995; Ciacci-Zanella et al., 1998). The ability of cells to escape apoptosis 
is critical in the development of cancer and FB1 may selectively manipulate apoptotic 
pathways leading to resistance to apoptosis, thus allowing altered growth capabilities.  
Interestingly, the cancer promoting effects of FB1 are closely correlated with 
increased apoptosis and subsequent regenerative cellular proliferation (Dragan et al., 
2001). 
  
The mechanisms underlying the disparate observations with regard to FB1 and 
apoptosis are largely unknown. We investigated the effects of FB1 on apoptosis in 
HepG2 liver cells by using a quantitative assay for apoptosis identifying specific 
genes that interfere with FB1-induced apoptosis 
 
2. Material and Methods 
2.1 Materials 
The HepG2 (hepatocellular carcinoma) cells were purchased from Highveld 
Biologicals (Johannesburg, South Africa). Cell culture reagents were purchased from 
Whitehead Scientific (Johannesburg, South Africa). Cell Titre Glo, GSH-Glo, 
Caspase-8, -9 and -3/7-Glo luminometry assays were purchased from Promega 
(USA). Annexin V-FLUOS was obtained from Roche (South Africa) and the Human 
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Apoptosis RT² Profiler PCR Array (PAHS-012A) was purchased from Qiagen (USA). 
All other reagents and consumables were purchased from Merck (SA), unless 
otherwise stated.  
2.2 Cell culture and viability assay 
HepG2 cells were cultured (37oC, 5% CO2) to confluency in 25cm3 flasks in complete 
culture media (CCM) [Eagle’s minimum essential medium, 10% foetal calf serum, 
1% L-Glutamine and 1% penstrepfungizone]. The cytotoxicity of FB1 in HepG2 cells 
was measured using the 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium 
bromide (MTT) assay. Cells (20,000/well) were incubated for 24hr with varying FB1 
concentrations (0µM to 1000µM) in triplicate in a 96-well microtitre plate together 
with the respective control treatments (cells incubated with CCM only).  The cells 
were then incubated with the MTT substrate (5 mg/ml in 0.1M phosphate buffered 
saline (PBS)) for 4hr.  Thereafter all supernatants were aspirated, and DMSO (100 
µl/well) was added to the wells.  Finally the optical density was measured at 570 nm 
and a reference wavelength of 690 nm with an ELISA plate reader (Bio-Tek µQuant). 
The data was translated to percentage cell viability versus concentration of FB1 
treatment from which the half maximal inhibitory concentration (IC50) was 
determined.  This IC50 value was used in all experiments, except when a dose 
dependent (200µM, 100µM, 50µM, 0µM) effect of FB1 on BIRC-8/ILP-2 induction 
was evaluated. 
2.3 Annexin-V-FLUOS assay 
The annexin-V-Fluos assay (Roche, SA) was used to determine phosphatidylserine 
(PS) translocation. To each flow cytometry tube, 100µl of staining buffer, 100µl of 
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annexin-V-Fluos labeling solution (annexin-V: propidium iodide (PI): staining buffer 
(1:1:50 vol/vol/vol)) and 100µl of cell suspension was added, and incubated in the 
dark (15min, RT). Cells were analyzed on a FACS Calibur (BD Biosciences, USA) 
flow cytometer. Data were analyzed using CellQuest PRO v4.02 software (BD 
Biosciences, USA). Cells were gated to exclude cellular debris using FlowJo v7.1 
software (Tree Star, Inc, USA). Approximately 50,000 events were analyzed for 
apoptotic, necrotic and live cells. The results were expressed as a percentage of the 
total events. 
2.4 Assessment of caspase activity 
Caspase-3/-7, -8 and -9 activities were detected with Caspase-Glo® assays (Promega, 
Madison, USA). As per manufacturer’s protocol, Caspase-Glo®-3/-7, -8 and -9 
reagents were reconstituted and added to wells (in six replicates) of an opaque 96-well 
microtitre plate (40µl of reagent per 100µl of 20,000 cells/well). Samples were mixed 
and incubated in the dark (30min, RT). The luminescent signal was measured on a 
Modulus™ microplate luminometer (Turner Biosystems, Sunnyvale, USA). Caspase-
3/-7, -8 and -9 activities were expressed as relative light units (RLU). 
2.5 Apoptosis Array  
Following treatment, cells were rinsed (0.1M PBS) and 500µl 0.1M PBS was added 
to each flask. An aliquot of 500µl Tri Reagent® Solution (Ambion, USA) was added 
to each flask for isolation of total RNA. Small RNA was isolated using the RNeasy 
Isolation Kit (Qiagen, USA) as per standard methods and quantified 
spectrophotometrically using a Nanodrop 2000.  cDNA was synthesised using the 
RT2 First-Stand Kit (Qiagen, USA) which contained an effective genomic DNA 
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elimination step and a built-in external RNA control. The Human Apoptosis RT² 
Profiler PCR Array (PAHS-012A) was used to profile the expression of 84 key genes 
involved in programmed cell death.  Data analysis was performed using 
SABiosciences’ PCR array data analysis software. Relative changes in gene 
expression were calculated using the comparative threshold cycle (Ct), delta delta 
(DDCt) method. This method first subtracts the Ct (threshold cycle number) of the 
gene-average Ct of the housekeeping genes on the array to normalize for the amount 
of RNA per sample. Finally the DDCt was calculated as the difference between the 
normalized average Ct of the irradiated group and the normalized average Ct of the 
untreated control group. This DDCt value was raised to the power of 2 to calculate the 
degree of change.  
2.6 Validation of Birc-8 expression by quantitative PCR 
Total RNA was extracted using the Tri Reagent® Solution (Ambion) and was reverse 
transcribed using the iScript cDNA synthesis kit (BioRad, SA). Real-time PCR was 
performed using the iQ Superscript reagent (BioRad, SA). Levels of mRNA for BIRC 
8 (sense: 5’ GTGAGCGCTCAGAAAGACACTAC 3’, antisense: 5’ 
CACATGGGACATCTGTCAACTG 3’) was quantified with standardization of levels 
to the average of a housekeeping gene: GAPDH (sense: 5’ 
CAACAGCCTCAAGATCATCAGC 3’, antisense: 5’ 
TGAGTCCTTCCACGATACCAAAG 3’).  
The PCR conditions were as follows: 40 cycles of a denaturation step (95oC, for 30s), 
an annealing step (56oC, for 15s), a plate read and an elongation step at 72oC. This 
was followed by a melt curve from 60oC to 95oC, with a plate read every 2oC held for 
30s. For BIRC 8 and GAPDH, the final concentrations of primers used were 300nM 
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and 100nM, respectively. The method described by Livak and Schmittgen (2001) was 
used to calculate a relative fold change of each gene from cycle threshold values 
(Livak and Schmittgen, 2001). All experiments were conducted in triplicate and 
repeated at least thrice.   
 
2.7 Western blot of Birc-8/ILP-2 and Smac/DIABLO protein level 
Isolated protein samples (HepG2 crude protein extract standardized to 1mg/ml) were 
denatured by boiling for 10min with a 1:1 dilution with 1× Laemmli sample buffer 
(0.375M Tris–HCl pH 6.8; 10%, w/v SDS; 3%, v/v glycerol; 0.2%, w/v bromophenol 
blue; 12% β-mercaptoethanol in dH2O). For each sample, 100µg of total protein was 
loaded on a 10% polyacrylamide gel, run at 150V. Transfer onto nitrocellulose 
membrane was conducted at 350mA for 1h. Membranes were blocked for 1h with 
blocking buffer containing 5% non-fat dry milk in Tris buffered saline (TTBS, 25mM 
Tris pH 7.6, 150mM NaCl, 0.05% Tween 20).  
Membranes were probed overnight at 4°C with anti-ILP2 (ab9664) (Abcam, USA), 
anti-Smac/DIABLO (ab110291) and anti-β actin (Sigma, USA) diluted to 1:1000 in 
3% BSA in TTBS.  A horseradish peroxidase-conjugated secondary antibody diluted 
to 1:5,000 in 1% bovine serum albumin (BSA) in TTBS was used to allow detection 
of appropriate bands using LumiGLO® Chemiluminescent Substrate Kit (KPL). 
Images were captured on the Alliance 2.4 gel documentation system (UViTech, UK). 
All experiments were conducted at least thrice and blots were analysed using 
UViBand analysis software (UViTech, UK). 
 
	   101	  
2.8 Statistical evaluation 
Statistical analyses were performed using GraphPad Prism version 5.00 software 
package (GraphPad PRISM®). Data are expressed as mean  ±  standard error of the 
mean (sem). Comparisons were made using Mann Whitney Tests, unpaired t tests 
with Welch Correction or the One-way analysis of Variance with Dunn’s multiple 
comparisons posttest. Statistical significance was set at 0.05. 
 
3. Results 
3.1 Dose response studies 
A dose response was determined using serially diluted concentrations of FB1 (0 - 
1000µM) in HepG2 cells over 24h. Analysis of the dose response curve showed that 
200µM FB1 was sufficient to cause 50% HepG2 cytotoxicity (IC50)  (Figure 5.1A).  
This concentration of FB1 was used in all subsequent experiments unless otherwise 
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Figure 5.1 A: Dose dependent decline in HepG2 cell viability following treatment for 
24hours with a range (0-1000µM) of concentrations of FB1. Data represented as a 
percentage of the means from 3 separate experiments. Where *p<0.05, **p<0.01, 
***p<0.001 compared to 0µM; B: Percentages of apoptotic and C: necrotic HepG2 
cells after treatment with FB1 for 24hours (* p < 0.005 (-8.841 to -1.359, 95% CI of 
difference); ** p < 0.0004 (-21.94 to -14.46, 95% CI of difference); Mann Whitney 
Test; D-F: Apoptotic caspase activity. Initiator Caspases -8, -9, and executioner 
caspases C: -3/7. * p < 0.005  (5.56 x 106 to 6.63 x 106, 95% CI of difference) ** p < 
0.0004 (-7.23 x 106 to -6.19 x 106, 95% CI of difference). 
3.2 Apoptosis studies 
Next we investigated the effects of FB1 on HepG2 cell apoptosis by examining 
translocation of PS residues on the plasma membrane using the Annexin-V assay.  
FB1 (200µM) significantly increased (2.5 fold) the percentage of PS externalization in 
HepG2 cells  – an indication of early apoptotic cell death.  Cell death due to necrosis 
was ruled out by assessing incorporation of PI. Less than 5% necrosis was observed 
and control cells did not differ significantly from the FB1 treatment (Figure 5.1B-C). 
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The caspases are the molecular machinery of apoptosis and the activities of key 
initiator caspases (-8 and -9) and executioner caspases (-3 and -7) in HepG2 cells after 
treatment with FB1 was determined.  Interestingly, despite the increase in PS 
translocation by FB1, there were differences in caspase activity after treatment (Figure 
5.1D-F).  
To address this disparity in measurements of conventional markers of apoptosis, we 
systematically investigated changes in expression of all known apoptosis-associated 
genes by qPCR arrays. In total we evaluated the expression of 84 apoptosis related 
genes (Figure 5.2A). Fold change profile plots showed that of all genes evaluated, 
BIRC-8/ILP-2 was significantly up regulated (more that 8-fold) after treatment with 
FB1 (Figure 5.2B). In addition both death-associated protein kinase 1 (DAPK1) and 
caspase associated recruitment domain 8 (CARD) were also elevated with deceased 
expression of caspases -9, -3 and -7 (Figure 5.2B)   
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Figure 5.2: Fold change profiles for apoptotis-associated genes in HepG2 cells after 
FB1 treatment with 200µM FB1. (A)  Heatmap of relative expression of all 84 genes in 
apoptosis array. It shows that in general, basal expression of apoptosis relevant genes 
are higher. Upon treatment, it seems that most of these genes are repressed relative to 
the control. There are however some clusters of induced genes. (B) Some examples of 
induced genes include Birc8/ILP2, DAPK1 and CARD8. The usual apoptosis 
machinery (Caspases -3, -7, -9) seem to be repressed as early as the transcript level. 
(C)  Fold change profile plot shows  BIRC-8/ILP-2 was significantly up-regulated by 
FB1 p=0.0038; Mann Whitney Test). 
 
	   105	  
3.3 Evaluation of BIRC-8/ILP-2 induction and Smac/DIABLO expression 
To validate the induction of BIRC-8/ILP-2 by FB1 we performed independent qPCR 
experiments. These analyses showed that 200µM FB1 was indeed able to up-regulate 
expression of BIRC-8/ILP-2 in HepG2 cells after 24hr of culture by more that 4-fold 
(Figure 5.3A). Immuno-blot experiments showed that increases observed in the 
BIRC-8/ILP-2 transcript fully translated to increases in BIRC-8/ILP-2 protein levels 
(Figure 5.3B). Fumonisin B1 also caused a 1.7-fold decrease in Smac-DIABLO 
protein levels (Figure 5.3C). 
 
 
Figure 5.3: BIRC-8/ILP-2 transcript (A) and protein (B) expression up-regulated and 
Smac/DIABLO protein expression (C) down-regulated in HepG2 cells after FB1 
treatment with 200µM FB1. The ILP-2 protein levels was significantly up-regulated 
by FB1 (2.3 fold vs. control, p=0.003; Mann Whitney Test) and Smac/DIABLO 
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3.4 Dose dependent effects of FB1 
We next tested whether the effects of FB1 with respect to BIRC-8/ILP-2 induction 
were dose related.  From the IC50 dose, FB1 concentration was serially decreased by 
two-fold (200µM, 100µM, 50µM, 0µM) and thereafter HepG2 cells were treated for 
24hr. Measurements of BIRC-8/ILP-2 transcripts by qPCR show no difference up to 
50µM FB1. However there is a sharp and significant increase in BIRC-8/ILP-2 
expression at 100µM and 200µM FB1 (Figure 5.4A). Immuno-blots clearly show that 
ILP-2 protein levels track with a similar trend. There are no significant changes in 
BIRC-8/ILP-2 protein from baseline up to 50µM FB1. FB1 concentrations above 
50µM caused significant increases in BIRC-8/ILP-2 protein levels (Figure 5.4B). 
These data suggest that induction and stabilization of BIRC-8/IL-2 is dependent on 
dose of FB1. Interestingly, caspase-8 /-9 activities correspond directly with dose of 
FB1. Up to 50µM FB1 there is a steady and significant increase in caspase-8/-9 
activity. However, activity of both caspases diminishes at higher doses of FB1 as 
BIRC-8/ILP-2 is induced (Figure 5.4C). Taken together, these data strongly suggest 
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Figure 5.4: Dose dependent induction of BIRC-8/ILP-2 transcript (A, n = 6 replicates 
per dose) and dose dependent increase in BIRC8/ILP-2 protein expression (B, n = 3 
replicates per dose) in HepG2 cells after FB1 treatment. * p<0.0001 ANOVA with 
Bonferroni post test (0µM vs. 100µM and  0µM vs. 200µM) (C) Caspase activity in 
HepG2 cells at different FB1 concentrations (n = 4 replicates per dose).  * p<0.0001 
ANOVA with Bonferroni post test (0µM vs. 50µM). 
 
4. DISCUSSION 
Fumonisin B1 has been implicated in the nephrotoxicity, hepatotoxicity and 
carcinogenicity in several animal systems (Bulder et al., 2012; Gelderblom and 
Marasas, 2012). The contamination of corn by FB1 results in the inevitable exposure 
of humans to this mycotoxin. Since early 1970’s studies on FB1 have associated it 
with mitogenic and apoptotic inducing properties and literature indicates distinct 
species-specific toxicity. In China, South Africa and Iran, FB1 has been linked with an 
increased risk of esophageal cancer (Shephard et al., 2007; Shephard et al., 2002; Sun 
et al., 2007; Sun et al., 2011) and with stunted growth in Tanzania (Kimanya et al., 
2010). The mechanism of action of FB1 which occurs via competitive inhibition of 
ceramide synthase has been well described (van der Westhuizen et al., 2004).  
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There are several conflicting mechanisms of molecular toxicity in different organ 
systems (Gelineau-van Waes et al., 2005; Marasas et al., 2004; Mobio et al., 2003; 
Voss et al., 2011). It has been established that following the biological distribution of 
FB1, the liver and kidneys retain the highest concentrations (Voss et al., 2001). The 
current study evaluated the acute toxicity of FB1 on human derived hepatocellular 
carcinoma (HepG2) cells. 
With the intention of completing the battery of cytotoxicity tests recommended by 
Miret et al. (2006), an evaluation of programmed cell death and necrosis markers 
were evaluated (Miret et al., 2006).  FB1 did not cause an increase in necrosis but 
significantly increased the externalization of PS - an early marker of apoptosis. The 
initiator caspase-8 involved in the extrinsic activation of the apoptosis pathway and 
the late activated executioner caspases-3/-7 was not affected by FB1 at 200µM. In 
addition FB1 did not influence HepG2 caspase-9 activity as compared to the control. 
Programmed cell death is a tightly regulated process that occurs via distinguished 
activation pathways. Our findings, however, suggests that HepG2 cells treated with 
FB1 is able to translocate PS to the external cell membrane in the absence of caspase 
activation. This process has been previously described as ‘caspase-independent PS 
externalisation’ (Ferraro-Peyret et al., 2002; Quignon et al., 1998; Thon et al., 2005). 
One mechanism described that caspase-dependent cell death via the extrinsic pathway 
is dependent on ceramide as a mediator of TNF-induced apoptosis, but was still active 
in the presence of caspase inhibitors and did require a change in mitochondrial 
membrane permeability or cytochrome C release (Thon et al., 2005).  
Following exposure to FB1, an inhibitor of ceramide synthase, ceramide synthesis 
decreases but ceramide is then sequestered from complex sphingolipids, altering cell 
membrane integrity potentially increasing PS exposure. The second mechanism of 
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caspase-independent cell death suggested that the process occurs via activation of 
oncogenes and viral associated structural change in nuclear material (Quignon et al., 
1998). This is important as we previously reported the localization of FB1 in the 
cytoplasm, mitochondria as well as the nuclei of oesophageal cancer cells by 
immunocytochemistry and transmission electron microscopy (Myburg et al., 2002). 
To further verify our results we evaluated the mRNA levels on a panel of 84 apoptosis 
associated genes. Only one gene, from the inhibitor of apoptosis (IAP) protein family 
– BIRC 8 was significantly increased (8 fold - 200µM FB1) relative to the untreated 
control cells.  The AIP’s inhibit apoptosis by either inhibiting enzyme activity of the 
caspases, or via ubiquitin-targeted proteasome degradation (Eckelman and Salvesen, 
2006; Eckelman et al., 2006). Birc-8 specifically is referred to as an IAP-like protein 
2 (ILP-2) and it contains all of the surface elements required for caspase-9 inhibition. 
The BIR domain, however, is thought to have an intrinsically unstable domain due to 
a natural amino-terminal truncation and this compromises the molecules ability to 
function as a caspase inhibitor (Shin et al., 2005).  In this study FB1 was able to 
significantly increase both the mRNA (5.7 fold) and protein expression (2.3 fold) of 
BIRC-8 in HepG2 cells (Figures 5.3A and 5.3B). FB1 initiated apoptosis via the 
intrinsic pathway as indicated by caspase-9 activity, but the lack of executioner 
caspase -3/-7 activity can be attributed to increased expression of both ILP-2 protein 
BIRC-8 mRNA. Furthermore, Smac/DIABLO, a mitochondrial pro-apoptotic protein, 
is able to antagonise the inhibitory effects of XIAP due to the presence of IAP-
binding protein motifs that fit into the BIR domains of XIAP (Chai et al., 2000; 
Fischer and Schulze-Osthoff, 2005).  
We showed that FB1 caused a decrease in protein expression of Smac/DIABLO 
(Figure 5.3C). A recently published finding by our group illustrated the effect of FB1 
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on microRNA (miRNA) expression in HepG2 cells and found a significant down-
regulation of both miR-27b and miR-27a (Chuturgoon et al., 2014b). Interestingly, 
both miR-27a and miR-27b also target and specifically bind to XIAP (NM_001167) in 
the 3’ UTR (position 6748-6754) with an exact match to positions 2-8 of the mature 
miRNA seed sequence. Thus elevated IAP components observed in FB1 treatment 
may also be attributed to compromised post-transcriptional regulation by miR-27a/b. 
 Therefore, functionally compromised cells that persist as a result of incomplete 
apoptosis may have a high propensity to become oncogenic.  The over expression of 
DAPK1 suggests a cytoprotective effect that is mediated through both the intrinsic 
and extrinsic apoptotic signaling pathways and results in inhibition of cytochrome c 
release from the mitochondria as well as inhibition of caspase-3 and caspase-9 
activity. This suggests that DAPK1 is a negative regulator of TNF-induced apoptosis 
(Jin et al., 2002).  Overexpression of CARD8 was noted in some cancers that suppress 
caspase mediated apoptosis (Bagnall et al., 2008).    
Our data clearly shows that FB1 modulates apoptosis of HepG2 cells in a complex 
manner – and it is not a matter of simply switching on or off.  The HepG2 cells do 
perceive toxic stress, as indicated by membrane changes and oxidation (Reactive 
oxygen species/GSH – Addendum C), but more importantly these cells can reverse 
apoptosis by the induction of the IAP machinery in response to FB1.   
5. Conclusion: 
In conclusion, our results show that FB1 inhibits apoptosis in HepG2 cells by inducing 
increased expression of Birc-8/ILP-2 that may then lead to liver tumourigenesis. 
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FB1, a type 2B carcinogen, is known to promote tumourigenesis but its cancer 
initiating properties have not been conclusively proved.  Many studies on laboratory 
animals showed that FB1 possesses liver cancer initiating effects. 
FB1 exhibited cancer initiating properties in male BD IX, Fischer 344 and Sprague 
Dawley rats (Gelderblom et al., 1994;  Gelderblom et al., 2001; Gelderblom et al., 
2008; Mehta et al., 1998).  FB1 can initiate cancer in rat liver similar to other 
genotoxic carcinogens.  However, rat liver cancer initiation was only effected after 
prolonged feeding and depended on the dose of FB1.  An important observation was 
that the levels of DNA mutations occurred at a significantly lower rate when 
compared to other genotoxic agents (Gelderblom et al., 1992; Norred et al., 1992).  In 
comparison to other genotoxins, cell proliferation associated with hyperplasia was 
minimal, while stimulation of regenerative cell proliferation enhanced the cancer 
initiating potency of FB1 (Gelderblom et al., 2001).   
Currently, there is minimal evidence about the nature of the initiating step of either 
genotoxic or non-genotoxic carcinogens such as FB1, although parameters such as 
protein and RNA can be altered independently from changes to the DNA (Gelderblom 
and Marasas, 2012).  Apoptosis plays a critical role in the outcome of the cancer 
initiating event, as initiated cells are more prone to undergo apoptosis (Bursch et al., 
1992).  FB1 induces necrosis as well apoptosis in the liver that could determine the 
outcome of cancer initiation (Gelderblom et al., 2008). 
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This study showed that FB1 has epigenetic and apoptotic properties in a human liver 
cell line (HepG2).   Firstly, FB1 (with an IC50 value of 200 µM) disrupted DNA 
methylation and induced chromatin modifications in the HepG2 cells.   The data 
shows, for the first time, that FB1 induced global DNA hypomethylation in human 
hepatoma cells by altering the balance of DNA methylases/demethylases, thereby 
disrupting the structural integrity of DNA. FB1 significantly decreased the 
methyltransferase activities of DNMT1, DNMT3A and DNMT 3B, and significantly 
up-regulated the demethylases (MBD2 expression and enzyme activity).  In addition, 
FB1 also significantly increased the expression of two histone demethylase genes 
KDM5B and KDM5C (members of the Jumonji family of proteins that catalyse the 
demethylation of tri- and dimethylated lysines).  They specifically act on tri- and 
dimethylated lysine 4 on histone H3 (H3K4) (only found at transcribed genes) and are 
associated to euchromatin and active transcription.  Trimethylated H3K4 is highly 
enriched around transcriptional start sites whilst dimethylated H3K4 is present 
throughout the coding region of transcribed genes.  KDM5B is regulated by the 
oncogene c-ErbB2 and is highly expressed in ductal breast carcinomas and is 
associated with the malignant phenotype in breast.  In addition to its role in promoting 
cancer, KDM5B is needed for the proliferation of MCF-7 breast cancer cells and 
tumour growth of mammary carcinoma cells in nude mice; its target genes in breast 
cancer proliferation have been identified as BRCA 1, CAV 1 and HOXA5.  FB1 
increased KDM5B and KDM5C expression in liver HepG2 cells that will result in 
increased H3K4Me3/Me2 demethylation. A consequence of this increased H3K4 
demethylation will disrupt its role as a transcriptional repressor. 
FACS data (using anti- 5’-MeCyt) showed a significant increase in global DNA 
hypomethylation, resulting in gross changes in structural DNA, an observation 
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supported by the significantly long DNA comet tails. This is the first evidence that 
shows FB1 induced epigenetic DNA hypomethylation in human liver cells leading to 
chromatin instability and aberrant transcriptional activation.   
FB1 results in aberrant gene expression in liver cells; the cells may alter their normal 
miRNA profiles and create a micro-environment which facilitates carcinogenesis. It is 
likely that the cells may change their miRNA milieu in response to FB1 toxicity. Five 
miRNAs were down regulated (miR-27b, miR-27a, miR-30c, miR-181d and miR-
135b) with miR-27b significantly down regulated by 11 fold.   MiR-27b modulates 
CYP1B1 expression, suggesting an additional mode of hepatic neoplastic 
transformation by FB1.  CYP1B1 catalyses the metabolic activation of many pro-
carcinogens including PAHs and aryl amines, and the metabolism of oestradiol to 
form 4-hydroxyoestradiol, which causes DNA damage and contributes to oestrogen-
dependent cancers.   Liver cells transfected with the mimic to miR-27b showed that 
FB1 significantly down-regulated expression of miR-27b; whilst CYP1B1 mRNA and 
protein expression was significantly upregulated by 1.8- fold and 2.6- fold 
respectively. CYP1B1 is post-transcriptionally regulated by miR-27b in HepG2 by 
FB1. FB1- induced epigenetic modulation of miR-27b in hepatic cells may be an 
additional mode of hepatic neoplastic transformation. 
The ability of cells to escape apoptosis is critical in the development of cancer and 
FB1 may selectively manipulate apoptotic pathways leading to resistance to apoptosis, 
thus allowing altered growth capabilities.  Interestingly, the cancer promoting effects 
of FB1 are closely correlated with increased apoptosis and subsequent regenerative 
cellular proliferation.  Using a panel of 84 apoptosis associated genes FB1 
significantly increased only one gene, from the IAP protein family – BIRC 8 (8 fold).  
The AIP’s inhibit apoptosis by either inhibiting caspases, or via ubiquitin-targeted 
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proteasome degradation. Birc-8 or ILP-2 contains the surface elements required for 
caspase-9 inhibition.  FB1 significantly increased both the mRNA and protein 
expression of BIRC-8/ILP-2 in HepG2 cells. FB1 initiated apoptosis via the intrinsic 
pathway as indicated by increased caspase-9 activity, but the lack of executioner 
caspase-3/-7 activity can be attributed to increased expression of both ILP-2 protein 
and BIRC-8 mRNA. Further, Smac/DIABLO protein expression, a mitochondrial pro-
apoptotic protein, was decreased by FB1. FB1 influences microRNA expression in 
HepG2 cells. Thus elevated AIP components observed in FB1 treatment may also be 
attributed to compromised post-transcriptional regulation by miR-27a/b. 
The data clearly shows that FB1 modulates liver cell apoptosis in a complex dose-
dependent regulation of pro- and anti-apoptotic molecules.  The HepG2 cells do 
perceive toxic stress, but more importantly these cells can reverse apoptosis by the 
induction of the IAP machinery in response to FB1.   
Finally, taken together, this study shows that FB1 possess epigenetic properties by 
inducing global DNA hypomethylation, modulating miRNA expression and 
increasing expression of the IAP protein (BIRC8/ILP-2); FB1 is a genotoxic agent that 
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Addendum A 
 
HepG2 cell viability treated with a range of FB1 concentrations 
 
HepG2 cells were treated with a range (0- 1000µM) of concentrations of FB1 over 
24hours. A dose dependent decline in HepG2 cell viability was observed and an IC50 
value of 200µM was determined (Addendum Table 1 and Figure 1). 
Addendum A-Table 1: HepG2 cell viability treated with a range of FB1 












FB1 [µM] Mean Viability ± SEM 95% CI of Difference 
0 100.0 ± 10.0 -38.86 to 15.02 
10 111.9 ± 8.8 -24.25 to 29.63 
50 97.3 ± 10.4 ** 14.02 to 67.90 
100 59.0 ± 2.5 *** 23.44 to 77.32 
200 49.6 ± 3.5 * 1.522 to 55.40 
300 71.5 ± 3.8 * 6.137 to 60.02 
400 66.9 ± 5.4 ** 17.10 to 70.98 
500 56.0 ± 3.3 *** 25.37 to 79.25 
800 28.1 ± 2.7 *** 44.98 to 98.86 
1000 36.4 ± 1.3 *** 36.71 to 90.59 
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Addendum A- Figure 1: A dose dependent decline in HepG2 cell viability following 
treatment for 24hr with a range (0-1000µM) of concentrations of FB1. Data 
represented as a percentage of the means from 3 separate experiments. Where 
*p<0.05, **p<0.01, ***p<0.001 compared to 0 µM. 
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Addendum B 
DNA hypomethylation by 5µM FB1 
Using FACs, methylation assays (anti-5’-MeCyt) on HepG2 cells were performed 
with 5µM FB1 (mitogenic concentration) after 24 hours incubation. At 5µM FB1 
induced hypomethylation (Addendum B -Figures 2A and 3), but the hypomethylation 
was not significant as that observed at 200µM FB1 (Addendum B -Figures 2B and 3). 
 
 
Addendum B- Figure 2: Histograms showing global DNA hypomethylation in 
HepG2 cells after 24hr culture with FB1.  A: 5-methylcytosine detection in 5µM FB1 
treatment. B: 5-methylcytosine detection in 200µM FB1 treatment.   
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Addendum B- Figure 3: Flow cytometric detection of 5-methylcytosine in HepG2 
cells (* p = 0.0006; One way ANOVA). 
Thus using both a low concentration of FB1 (5µM; mitogenic) and a cytotoxic 
concentration (200µM; IC50) – hypomethylation was induced in HepG2 cells, with 
significant hypomethylation at the 200µM FB1 concentration. 
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ADDENDUM C 
 
Oxidative stress induced by FB1 
 
Lipid peroxidation assay 
The by-product of lipid peroxidation, malondialdehyde (MDA), was assessed using 
the thiobarbituric acid reactive substances (TBARS) as an indicator of oxidative 
damage in the cell. Briefly, 200µl of 2% H3PO4, 400µl of 7% H3PO4, 400µl of 
TBA/BHT solution and 200µl of 1M HCL were added to thoroughly cleaned test 
tubes. The supernatants from each sample (100µL) was added to the relevant test 
tube. A positive control was prepared by adding 1µL MDA to a test tube. All tubes 
were incubated in a water bath (100°C, 15min) and after cooling; butanol (1.5ml) was 
added to each tube, vortexed for 10 seconds and allowed to separate into two distinct 
phases. 100µL of the butanol phase (upper phase)  was transferred in triplicate into a 
96-well microtitre plate and read using a spectrophotometer (Bio-tek µQuant) at 
532/600nm. Results are expressed as mean optical density which correlates directly to  
MDA levels. 
 
Quantification of Glutathione                                               
Glutathione-Glo™ Assay (Promega) was used according to manufacturer’s guidelines 
to quantify glutathione (GSH) levels. 50µl from each sample (MOE treated and 
untreated control) was added in six replicates to the wells of an opaque polystyrene 
96-well microtitre plate. GSH standards (0-50µM) were prepared from a 5mM stock 
diluted in de-ionised water. 50µl of each GSH standards and 50µl of the GSH-Glo™ 
Reagent 2X was added per well and incubated in the dark (30min, RT). Reconstituted 
Luciferin Detection Reagent (50µl) was added per well and incubated (15min, RT). 
	   128	  
The luminescence was measured on a Modulus™ microplate luminometer (Turner 
Biosystems, Sunnyvale, USA). The data was analysed and expressed as relative light 





Addendum C- Figure 4: FB1 increased both MDA levels (lipid peroxidation) and 
intracellular GSH levels inHepG2 cells 
 
 
 
 
